This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at <https://www.tga.gov.au/reporting-problems>.

▼

# Australian PI – OLUMIANT (baricitinib)

# Name of the medicine

Baricitinib

# Qualitative and quantitative composition

OLUMIANT 2 mg film-coated tablets  
Each film-coated tablet contains 2 mg baricitinib

OLUMIANT 4 mg film-coated tablets  
Each film-coated tablet contains 4 mg baricitinib

For the full list of excipients, see section 6.1 [List of excipients](#_List_of_excipients)

# Pharmaceutical form

Film-coated tablet (tablet).

OLUMIANT 2 mg film-coated tablets  
Light pink, oblong, debossed with “Lilly” script on one side and “2” on the other.

OLUMIANT 4 mg film-coated tablets  
Medium pink, round, debossed with “Lilly” script on one side and “4” on the other.

The tablets contain a recessed area on each face of the tablet surface.

# Clinical particulars

## Therapeutic indications

**Rheumatoid Arthritis**

OLUMIANT is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately, or who are intolerant, to one or more DMARDs.

OLUMIANT can be taken as monotherapy or in combination with cDMARDs, including methotrexate (MTX).

**Atopic Dermatitis**

OLUMIANT is indicated for the treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy.

## Dose and method of administration

**Rheumatoid Arthritis**

Therapy with OLUMIANT should be initiated and monitored by a rheumatologist or specialist physician with expertise in the management of rheumatoid arthritis.

The recommended dose of OLUMIANT is 4 mg once daily. OLUMIANT may be used as monotherapy or in combination with cDMARDS.

A dose of 2 mg once daily may be acceptable for patients with an inadequate response to cDMARDs who have moderate disease severity, limited risk of progressive joint damage and moderate impairment of physical function (see section 5 PHARMACOLOGICAL PROPERTIES / PHARMACODYNAMIC PROPERTIES / [Clinical trials](#_Clinical_trials); section 4.4 SPECIAL WARNINGS AND PRECAUTIONS / [Use in hepatic impairment](#_Use_in_hepatic), [Use in renal impairment](#_Use_in_renal), [Effects on laboratory tests](#_Effects_on_laboratory)).

A dose of 2 mg once daily may also be considered for patients who have achieved sustained control of disease activity with 4 mg once daily and are eligible for dose tapering.

Combination with other JAK inhibitors has not been studied and is not recommended.

**Atopic Dermatitis**

Therapy with OLUMIANT should be initiated and supervised by a dermatologist or physician with expertise in the management of atopic dermatitis.

The recommended dose of OLUMIANT is 2 mg once daily (see section 5 PHARMACOLOGICAL PROPERTIES / PHARMACODYNAMIC PROPERTIES / [Clinical trials](#_Clinical_trials) on Atopic Dermatitis; section 4.4 SPECIAL WARNINGS AND PRECAUTIONS / [Use in hepatic impairment](#_Use_in_hepatic), [Use in renal impairment](#_Use_in_renal), [Effects on laboratory tests](#_Effects_on_laboratory)).

A dose of 4 mg once daily may also be considered for patients who have not achieved sustained control of disease activity with 2 mg once daily. Dose tapering to 2 mg once daily should be considered once the patient has achieved sustained control of disease with 4 mg once daily.

Treatment should be discontinued in patients who show no evidence of therapeutic benefit after 8 weeks of treatment with 4 mg.

OLUMIANT may be used as monotherapy or in combination with topical corticosteroids. Topical calcineurin inhibitors may be used.

Combination with biologic immunomodulators, other JAK inhibitors, cyclosporine or other potent immunosuppressants has not been studied in patients with atopic dermatitis and is not recommended.

OLUMIANT is given orally with or without food.

### Dose Modifications in Patients with Renal Impairment

The recommended dose of OLUMIANT in patients with moderate, Stage 3 renal impairment, (estimated glomerular filtration rate (GFR) 30 - ≤60 mL/min/1.73 m2) is 2 mg once daily. OLUMIANT is not recommended for use in patients with severe and end stage renal impairment Stage 4 & 5 (estimated GFR of <30 mL/min/1.73 m2) (see section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE / [Use in renal impairment](#_Use_in_renal)).

Subjects with creatinine clearance of <40 mL/min at baseline were excluded from participating in the Phase 3 baricitinib studies.

### Dose Modifications Due to Drug Interactions

The recommended dose of OLUMIANT in patients taking OAT3 inhibitors with a strong inhibition potential, such as probenecid, is 2 mg once daily (see section 4.5 [Interactions with other medicines and other forms of interactions](#_Interactions_with_other)).

### Managing Dose Interruptions or Adjustments

**Table 1 Laboratory Measures and Monitoring Guidance**

|  |  |  |
| --- | --- | --- |
| **Laboratory Measure** | **Action** | **Monitoring Guidance** |
| Lipid parameters | Patients should be managed according to local clinical guidelines for hyperlipidaemia | Week 0 and 12 weeks after initiation of treatment and thereafter according to local clinical guidelines for hyperlipidaemia |
| Absolute neutrophil count (ANC) | Treatment should be interrupted if ANC <1x 109 cells/L and may be restarted once ANC returns above this value | Before treatment initiation and thereafter according to routine patient management |
| Absolute lymphocyte count (ALC) | Treatment should be interrupted if ALC <0.5x 109cells/L and may be restarted once ALC returns above this value |
| Haemoglobin (Hb) | Treatment should be interrupted if Hb <8g/dL and may be restarted once Hb returns above this value |
| Hepatic transaminases | Treatment should be temporarily interrupted if drug-induced liver injury is suspected |

## Contraindications

OLUMIANT is contraindicated in patients with known hypersensitivity to baricitinib or any of the excipients in the product.

OLUMIANT must not be used in combination with bDMARDs.

## Special warnings and precautions for use

#### Infections

OLUMIANT treatment is associated with an increased rate of infections such as upper respiratory tract infections. OLUMIANT should be used with caution in patients with clinically important chronic, active, or recurrent infection. If an infection develops, monitor carefully and interrupt OLUMIANT therapy if the patient is not responding to standard therapy; do not resume OLUMIANT until the infection resolves.

#### Serious Infections

Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents including OLUMIANT (see section 4.8 [Adverse effects (Undesirable effects)](#_Adverse_effects_(Undesirable) / Adverse Reactions / [Infections](#_Infections)).

The most common serious infections reported with OLUMIANT included herpes zoster and cellulitis. Among opportunistic infections, oesophageal candidiasis and pneumocystis pneumonia were reported with OLUMIANT.

Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with OLUMIANT.

Caution should be used when treating the elderly and patients with diabetes.

A patient who develops a new infection during treatment with OLUMIANT should undergo prompt and complete diagnostic testing appropriate for an immunocompromised patient, appropriate antimicrobial therapy should be initiated and the patient should be closely monitored.

If a patient develops a serious infection, administration of OLUMIANT should be interrupted until the infection is controlled.

#### Tuberculosis

Patients should be screened for tuberculosis (TB) before starting OLUMIANT therapy. OLUMIANT should not be given to patients with active TB. Anti-TB therapy should be considered prior to initiation of OLUMIANT in patients with previously untreated latent TB.

#### Viral Reactivation

Viral reactivation, including cases of herpes virus reactivation (e.g. herpes zoster including cases that were disseminated beyond the primary or adjacent dermatomes) were reported in clinical studies with OLUMIANT. If a patient develops herpes zoster, OLUMIANT treatment should be interrupted until the episode resolves.

The impact of OLUMIANT on chronic viral hepatitis reactivation is unknown. Patients with evidence of active hepatitis B or C infection were excluded from clinical trials. Patients who were positive for hepatitis C antibody but negative for hepatitis C virus RNA, were permitted to enrol. Patients with hepatitis B surface antibody and hepatitis B core antibody, without hepatitis B surface antigen, were permitted to enrol; such patients should be monitored for expression of hepatitis B virus (HBV) DNA. Should HBV DNA be detected, consult with a hepatologist.

Screening for viral hepatitis should be performed in accordance with clinical guidelines before starting therapy with OLUMIANT.

#### Thrombosis

Events of deep venous thrombosis (DVT), arterial thrombosis and pulmonary embolism (PE) have been reported in patients receiving OLUMIANT.

For venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), 5 patients (0.5%) treated with baricitinib 4 mg reported events during the 24-week, randomised, placebo-controlled time period of the 6 Phase 2 and Phase 3 RA studies; no events were reported with the 2 mg dose or placebo during this time period. During the 0 to 52 week treatment period, venous thromboses were reported in 2 patients (0.6 per 100 patient years) treated with baricitinib 2 mg and 7 patients (0.8 per 100 patient years) treated with baricitinib 4 mg. In an analysis of extended data from the all baricitinib RA exposure population, 3770 patients (12151 patient years of observation) with RA, 57 patients experienced a VTE with an exposure-adjusted IR of 0.47 per 100 PY.

During the 16-week placebo-controlled period of atopic dermatitis studies, 1 patient treated with baricitinib 4 mg reported a VTE. In an analysis of extended data from all the baricitinib AD exposure population, including 2531 patients (2247 patient years of observation) with AD, an additional 2 patients reported VTE (one patient receiving 4 mg reported PE and one patient receiving 2 mg reported DVT). The overall IR was 0.13 per 100 PY.

OLUMIANT should be used with caution in patients with risk factors for deep vein thrombosis or pulmonary embolism (DVT/PE) such as older age, obesity, a medical history of DVT/PE, or patients undergoing surgery and immobilisation. Patients with multiple risk factors should be closely monitored and consideration should be given to appropriate VTE prophylaxis. If clinical features of DVT/PE occur, interrupt OLUMIANT, evaluate promptly, and institute appropriate treatment. OLUMIANT should only be recommenced once the patient is established on appropriate treatment. Recurrent events of VTE have been reported in some patients recommencing treatment with OLUMIANT.

#### Malignancy

The risk of malignancy, including lymphoma, is increased in patients with rheumatoid arthritis. Immunomodulatory medicinal products may increase the risk of malignancy.

In the placebo-controlled phase 2/3 clinical studies in rheumatoid arthritis patients, with data up to 24 weeks, 2 malignancies (excluding NMSC) were diagnosed in 2 patients receiving baricitinib 4 mg, compared to 2 malignancies (excluding NMSC) in patients in the placebo group. There were no cases of lymphoma reported during the placebo-controlled studies. In the all baricitinib exposure population of 3464 patients (4214 patient-years of exposure) with RA, 31 patients were diagnosed with malignancies (excluding NMSC), with an exposure-adjusted IR of 0.7 per 100 PY.

#### Immunisations

No data are available on the response to vaccination with live vaccines in patients receiving OLUMIANT.

Use with live, attenuated vaccines during, or immediately prior to, OLUMIANT therapy is not recommended. Prior to initiating OLUMIANT, it is recommended that all patients be brought up to date with all immunisations in agreement with current immunisation guidelines. The interval between live vaccinations and initiation of OLUMIANT therapy should be in accordance with current vaccination guidelines regarding immunosuppressive agents.

The influence of baricitinib on the humoral response to non-live vaccines was evaluated in 106 RA patients under stable treatment with baricitinib 2 or 4 mg, receiving inactivated pneumococcal 13-valent conjugate vaccine or tetanus vaccination. The majority of these patients (n=94) were co-treated with methotrexate. For the total population, excluding one patient who had pneumococcal 13-valent conjugate vaccine prior to entry to the study, pneumococcal conjugate vaccination resulted in a satisfactory IgG immune response (a ≥2-fold increase from baseline in ≥6 pneumococcal serotypes) in 68.6% (95% CI: 59.1%, 76.8%) of the patients. In 43.1%(95% CI: 34.0%,52.8%) of the patients, a satisfactory IgG immune response (a ≥4-fold increase from baseline in patients with a baseline anti-tetanus IgG concentration ≥0.1 IU/mL) to tetanus vaccination was achieved.

### Use in hepatic impairment

No dose adjustment is necessary in patients with mild or moderate hepatic impairment. The use of OLUMIANT has not been studied in patients with severe hepatic impairment and is therefore not recommended.

### Use in renal impairment

Renal function was found to significantly affect OLUMIANT exposure. The recommended dose of OLUMIANT in patients with moderate, Stage 3 renal impairment, (estimated GFR 30 - ≤60 mL/min/1.73 m2) is 2 mg once daily. OLUMIANT is not recommended for use in patients with Stage 4 & 5 severe & end stage renal impairment (estimated GFR of <30 mL/min/1.73 m2). (See Table 1 section 4.2 [Dose and method of administration](#_Dose_and_method)). Patients with a creatinine clearance <40 mL/min were excluded from the Phase 3 studies therefore caution is advised in patients with creatinine clearance 30 - <40 mL/min.

### Use in the elderly

Age of ≥65 years or ≥75 years has no effect on OLUMIANT exposure (Cmax and AUC).

Safety information in patients ≥75 years is limited compared to younger patients and this should be taken into consideration when choosing the dose for these patients.

### Paediatric use

The safety and effectiveness of OLUMIANT have not been established in patients under 18 years of age.

### Effects on laboratory tests

#### Neutropenia

Absolute neutrophil counts (ANC) <1000 cells/mm3 were uncommonly reported in clinical trials. Avoid initiation or interrupt OLUMIANT treatment in patients with an ANC<1000 cells/mm3 (See Table 1 section 4.2 [Dose and method of administration](#_Dose_and_method)).

#### Lymphopenia

Absolute lymphocyte counts (ALC) <500 cells/mm3 were uncommonly reported in clinical trials. Avoid initiation or interrupt OLUMIANT treatment in patients with an ALC <500 cells/mm3 (See Table 1 section 4.2 [Dose and method of administration](#_Dose_and_method)).

#### Haemoglobin

Decreases in haemoglobin levels to <8 g/dL were reported uncommonly with baricitinib treatment. Avoid use of OLUMIANT treatment in patients with haemoglobin <8 g/dL (See Table 1 section 4.2 [Dose and method of administration](#_Dose_and_method)).

#### Lipids

Increases in lipid parameters were very common in the OLUMIANT treated patients in clinical trials. Elevations in low-density lipoprotein (LDL) cholesterol decreased to pre-treatment levels in response to statin therapy. Lipid parameters should be assessed approximately 12 weeks following initiation of OLUMIANT therapy. During 12 weeks of treatment, 33.7% of patients treated with OLUMIANT 4 mg, 20.3 % of patients treated with OLUMIANT 2 mg and 11.3 % of patients treated with placebo developed LDL-C ≥3.36 mmol/L (see section 4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS) / Adverse Reactions / [Lipids](#_Lipids)). Patients should be managed according to local clinical guidelines for hyperlipidaemia (See Table 1 section 4.2 [Dose and method of administration](#_Dose_and_method)). The effect of these lipid parameter elevations on long-term cardiovascular morbidity and mortality has not been determined.

#### Aminotransferases

Increases to ≥5 and ≥10x upper limit of normal (ULN) were uncommonly observed for both alanine transaminase (ALT) and aspartate transaminase (AST) in patients treated with OLUMIANT in clinical trials. If increases in ALT or AST are observed, and drug induced liver injury is suspected, OLUMIANT should be interrupted until this diagnosis is excluded (See Table 1 section 4.2 [Dose and method of administration](#_Dose_and_method)).

## Interactions with other medicines and other forms of interactions

### Potential for OLUMIANT to affect other drugs

#### Cytochrome P450 Enzymes

In vitro, baricitinib did not significantly inhibit or induce the activity of cytochrome P450 enzymes (CYPs 3A, 1A2, 2B6, 2C8, 2C9, 2C19, and 2D6). In clinical pharmacology studies, coadministration of baricitinib with the CYP3A substrates simvastatin, ethinyl estradiol, or levonorgestrel resulted in no clinically meaningful changes in the pharmacokinetics (Cmax and AUC(0-∞)) of these drugs.

#### Transporters

In vitro, baricitinib did not inhibit the transporters P-glycoprotein (Pgp) or organic anion transporting polypeptide (OATP) 1B1. In vitro, baricitinib does inhibit organic anionic transporter (OAT) 1, OAT2, OAT3, organic cationic transporter (OCT)1, OCT2, OATP1B3, breast cancer resistance protein (BRCP) and multidrug and toxic extrusion protein (MATE)1 and MATE2-K, but clinically meaningful changes to drugs that are substrates for these transporters are unlikely. In clinical pharmacology studies there were no clinically meaningful effects when baricitinib was coadministered with digoxin (Pgp substrate) or methotrexate (substrate of several transporters).

### Potential for other drugs to affect OLUMIANT

#### Cytochrome P450 Enzymes

In vitro, baricitinib is a CYP3A4 substrate. In clinical pharmacology studies, coadministration of baricitinib with ketoconazole (CYP3A inhibitor) resulted in no clinically meaningful effect. Coadministration of baricitinib with fluconazole (CYP3A/CYP2C19/CYP2C9 inhibitor) or rifampicin (CYP3A inducer) resulted in no clinically meaningful changes in the pharmacokinetics (Cmax and AUC(0-∞)) of baricitinib.

#### Transporters

In vitro, baricitinib is a substrate for OAT3, Pgp, BCRP and MATE2-K. In a clinical pharmacology study, probenecid (OAT3 inhibitor with strong inhibition potential) dosing resulted in approximately a 2-fold increase in AUC(0-∞) with no effect on Cmax or Tmax of baricitinib. Simulations with diclofenac and ibuprofen (OAT3 inhibitors with less inhibition potential) predicted minimal effect on baricitinib exposure. Coadministration of baricitinib with cyclosporine (Pgp/BCRP inhibitor) or methotrexate (substrate of several transporters) resulted in no clinically meaningful effects on baricitinib exposure.

### Medicines used for VTE

No clinical drug-drug interaction (DDI) studies with anticoagulants have been conducted. Based on the low DDI potential of baricitinib via enzymes and transporters, clinically meaningful DDI are not anticipated for coadministration of baricitinib with medicines commonly used for prophylaxis or treatment of VTE.

## Fertility, pregnancy and lactation

### Effects on fertility

In a combined male/female rat fertility study, baricitinib decreased overall mating performance and male copulation index following dosing at approximately 56x the maximum recommended human exposure (AUC) and induced a dose-related trend towards reduced male fertility index following dosing at approximately 12x the maximum recommended human exposure (AUC).

Baricitinib treatment also significantly decreased female conception index following dosing at approximately 85x human exposure at the maximum recommended dose (AUC) and induced a dose related trend towards decreased fertility index following dosing at approximately 24x the maximum recommended human exposure (AUC). In female rats there were decreased numbers of corpora lutea and implantation sites and increased pre-implantation loss following dosing at approximately 85x human exposure at the maximum recommended dose (AUC). Following dosing at approximately 24x the maximum recommended human exposure (AUC), reduced mean number of viable embryos/dam, reduced mean viable embryos and increased mean post-implantation loss occurred. The no-observed-effects-level (NOEL) for fertility and impaired early embryonic development was approximately 4x human exposure at the maximum recommended dose (AUC).

Since there were no effects on spermatogenesis (as assessed by histopathology) or semen/sperm endpoints in male rats or mating indices in either sex, the decreased overall mating performance was likely the result of effects on female fertility and/or early pre-implantation embryonic development.

Women of childbearing potential should take appropriate precautions to avoid becoming pregnant during treatment with OLUMIANT and for at least 1 week after the final treatment.

### Use in pregnancy

Pregnancy Category D

Effects on human foetal development are not known. Based on limited data in rats, baricitinib-associated radioactivity readily crosses the placenta (foetal:maternal ratio approximately 2; n=1). In a rat embryofoetal development study, dosing with baricitinib at maternotoxic doses (approximately ≥10x the human maximum recommended dose; AUC) caused increased incidences of adverse malformations (bent limb bones, rib malformations). An increased incidence of foetal rib variations were also noted at even higher maternal exposures (approximately 55x human exposure at the maximum recommended human dose; AUC). In a rabbit embryofoetal development study, dosing of rabbits at ≤30x human exposure at the maximum recommended dose (AUC comparison) was not associated with foetal malformations or variations. However, maternal dosing at approximately 30x human exposure at the maximum recommended dose (AUC comparison) was associated with a decreased mean number of live foetuses/litter (7% decrease), an increased number of late in utero deaths, and decreased foetal weight.

Although the human relevance of the findings in animal studies is uncertain, the JAK/STAT pathway is involved in cell adhesion and cell polarity, which can affect early embryonic development.

OLUMIANT should only be used during pregnancy if the potential benefit justifies the potential risk to the foetus.

Women of childbearing potential should take appropriate precautions to avoid becoming pregnant during treatment with OLUMIANT and for at least 1 week after the final treatment.

### Use in lactation

It is unknown whether baricitinib is present in human milk. Baricitinib was detected in the milk of lactating rats. Following maternal PO dosing at 2-22x human exposure at the maximum recommended dose (AUC), the maximum plasma levels in pups occurred at 8 hours (last time point measured) post-dose of the dam.

Breastfeeding is not recommended during OLUMIANT treatment.

## Effects on ability to drive and use machines

No specific studies have been conducted to assess driving ability or sedation. There are no known effects on the ability to drive and use machines associated with the use of OLUMIANT.

## Adverse effects (Undesirable effects)

### Adverse Events Reported in Clinical Trials

**Rheumatoid Arthritis**

The safety of OLUMIANT in patients with rheumatoid arthritis (RA) was evaluated in a clinical program consisting of one phase 1 multi-dose study (n=53), three phase 2 multi-dose studies (n=573), four phase 3 multicentre, randomised, double-blind, controlled studies (n=3100), and an ongoing long term extension study.

Tables 2 and 3 list the adverse events (regardless of causality) occurring in ≥1% of patients treated with OLUMIANT during the double-blind, RA controlled studies.

**Table 2 Summary of Adverse Events reported by ≥0.1% of patients treated with OLUMIANT (all causalities) – double-blind, placebo-controlled studies up to 16 weeks.**

| **Events** | **Trials Evaluating**  **OLUMIANT 4 mg**  **(6 Trials)**  **(up to 16 weeks)** | | **Trials Evaluating**  **OLUMIANT 2 mg and OLUMIANT 4 mg**  **(4 Trials)**  **(up to 16 weeks)** | | |
| --- | --- | --- | --- | --- | --- |
| **Placebo + cDMARDs  n=1070 (%)** | **OLUMIANT 4 mg + cDMARDs n=997 (%)** | **Placebo + cDMARDs  n=551 (%)** | **OLUMIANT 2 mg + cDMARDs n=479 (%)** | **OLUMIANT 4 mg + cDMARDs n=479 (%)** |
| **Blood and lymphatic system disorders** | | | | | |
| Anaemia | 22 (2.1) | 20 (2.0) | 8 (1.5) | 8 (1.7) | 6 (1.3) |
| **Gastrointestinal disorders** | | | | | |
| Nausea | 17 (1.6) | 28 (2.8) | 11 (2.0) | 13 (2.7) | 14 (2.9) |
| Diarrhoea | 35 (3.3) | 24 (2.4) | 21 (3.8) | 16 (3.3) | 12 (2.5) |
| Dyspepsia | 8 (0.7) | 14 (1.4) |  |  |  |
| Constipation | 15 (1.4) | 11 (1.1) | 9 (1.6) | 8 (1.7) | 5 (1.0) |
| Vomiting | 6 (0.6) | 13 (1.3) | 4 (0.7) | 11 (2.3) | 5 (1.0) |
| Abdominal paina | 15 (1.4) | 21 (2.1) | 8 (1.5) | 18 (3.8) | 9 (1.9) |
| **General disorders and administration site conditions** | | | | | |
| Fatigue | 14 (1.3) | 11 (1.1) | 8 (1.5) | 7 (1.5) | 8 (1.7) |
| Pyrexia |  |  | 3 (0.5) | 6 (1.3) | 6 (1.3) |
| Oedema peripheral |  |  | 8 (1.5) | 5 (1.0) | 2 (0.4) |
| **Hepatobiliary disorders** | | | | | |
| Hepatic function abnormal |  |  | 1 (0.2) | 5 (1.0) | 2 (0.4) |
| **Infections and infestations** | | | | | |
| Nasopharyngitis | 51 (4.8) | 53 (5.3) | 26 (4.7) | 16 (3.3) | 25 (5.2) |
| Upper respiratory tract infection | 39 (3.6) | 46 (4.6) | 25 (4.5) | 27 (5.6) | 31 (6.5) |
| Bronchitis | 30 (2.8) | 31 (3.1) | 19 (3.4) | 12 (2.5) | 14 (2.9) |
| Urinary tract infection | 29 (2.7) | 34 (3.4) | 14 (2.5) | 17 (3.5) | 16 (3.3) |
| Pharyngitis | 14 (1.3) | 23 (2.3) | 4 (0.7) | 10 (2.1) | 13 (2.7) |
| Gastroenteritis | 9 (0.8) | 16 (1.6) | 4 (0.7) | 7 (1.5) | 12 (2.5) |
| Influenza | 10 (0.9) | 18 (1.8) | 6 (1.1) | 6 (1.3) | 9 (1.9) |
| Herpes zoster | 4 (0.4) | 14 (1.4) | 2 (0.4) | 5 (1.0) | 9 (1.9) |
| Sinusitis | 12 (1.1) | 10 (1.0) | 6 (1.1) | 10 (2.1) | 6 (1.3) |
| Oral herpes | 4 (0.4) | 10 (1.0) |  |  |  |
| Rhinitis |  |  | 1 (0.2) | 6 (1.3) | 1 (0.2) |
| Cystitis |  |  | 5 (0.9) | 7 (1.5) | 1 (0.2) |
| **Injury, poisoning and procedural complications** | | | | | |
| Contusion |  |  | 7 (1.3) | 6 (1.3) | 2 (0.4) |
| **Investigations** | | | | | |
| Blood creatine phosphokinase increased | 6 (0.6) | 35 (3.5) | 3 (0.5) | 11 (2.3) | 24 (5.0) |
| Alanine aminotransferase increased | 10 (0.9) | 15 (1.5) | 6 (1.1) | 5 (1.0) | 8 (1.7) |
| Aspartate aminotransferase increased | 5 (0.5) | 14 (1.4) | 4 (0.7) | 2 (0.4) | 10 (2.1) |
| Weight increased | 5 (0.5) | 6 (0.6) | 2 (0.4) | 4 (0.8) | 4 (0.8) |
| **Metabolism and nutrition disorders** | | | | | |
| Hypercholesterolaemia | 14 (1.3) | 28 (2.8) | 7 (1.3) | 7 (1.5) | 16 (3.3) |
| Hyperlipidaemia | 8 (0.7) | 19 (1.9) | 6 (1.1) | 5 (1.0) | 9 (1.9) |
| Dyslipidaemia | 5 (0.5) | 10 (1.0) | 2 (0.4) | 6 (1.3) | 5 (1.0) |
| **Musculoskeletal and connective tissue disorders** | | | | | |
| Arthralgia | 17 (1.6) | 17 (1.7) | 10 (1.8) | 8 (1.7) | 11 (2.3) |
| Rheumatoid arthritis | 23 (2.1) | 14 (1.4) | 10 (1.8) | 5 (1.0) | 10 (2.1) |
| Back pain | 26 (2.4) | 12 (1.2) | 18 (3.3) | 14 (2.9) | 7 (1.5) |
| Muscle spasms |  |  | 3 (0.5) | 6 (1.3) | 5 (1.0) |
| Myalgia |  |  | 1 (0.2) | 4 (0.8) | 5 (1.0) |
| **Nervous system disorders** | | | | | |
| Headache | 32 (3.0) | 38 (3.8) | 22 (4.0) | 30 (6.3) | 20 (4.2) |
| Dizziness | 8 (0.7) | 14 (1.4) | 4 (0.7) | 7 (1.5) | 7 (1.5) |
| **Psychiatric disorders** | | | | | |
| Insomnia |  |  | 3 (0.5) | 5 (1.0) | 2 (0.4) |
| **Reproductive system and breast disorders** | | | | | |
| Erectile dysfunctionb |  |  | 0 | 0 | 1 (1.1) |
| **Respiratory, thoracic and mediastinal disorders** | | | | | |
| Cough | 17 (1.6) | 19 (1.9) | 9 (1.6) | 9 (1.9) | 13 (2.7) |
| Oropharyngeal pain | 5 (0.5) | 12 (1.2) | 3 (0.5) | 9 (1.9) | 11 (2.3) |
| Pulmonary embolism | 0 | 3 (0.3) | (0) | (0) | 2 (0.4) |
| **Skin and subcutaneous tissue disorders** | | | | | |
| Alopecia |  |  | 5 (0.9) | 0 | 9 (1.9) |
| Acne | 0 | 8 (0.8) | 0 | 1 (0.2) | 5 (1.0) |
| Rashc | 28 (2.6) | 18 (1.8) | 15 (2.7) | 9 (1.9) | 9 (1.9) |
| Swelling of the face | 1 (0.1) | 4 (0.4) | (0) | (0) | 1 (0.2) |
| Urticaria | 1 (0.1) | 2 (0.2) | (0) | 2 (0.4) | 2 (0.4) |
| **Vascular disorders** | | | | | |
| Hypertension | 17 (1.6) | 21 (2.1) | 6 (1.1) | 16 (3.3) | 15 (3.1) |
| Deep Vein Thrombosis | 0 | 2 (0.2) | 0 | 0 | 0 |

1. Includes abdominal pain, abdominal pain lower, abdominal pain upper.
2. denominator adjusted because event is specific to males: N=93 (placebo), N=93 (OLUMIANT 2 mg), N=88 (OLUMIANT 4 mg)
3. Includes rash, dermatitis, dermatitis contact, eczema, dermatitis allergic, rash maculo-papular, rash pruritic, rash pustular, drug eruption, rash erythematous, rash macular

**Table 3 Summary of Adverse Events reported by ≥1% of patients treated with OLUMIANT (all causalities) – double-blind, active-controlled study up to 24 weeks (RA-BEGIN).**

| **Events** | **Trial Evaluating**  **OLUMIANT 4 mg**  **(1 Trial)**  **(up to 24 weeks)** | | |
| --- | --- | --- | --- |
| **Methotrexate n=210 (%)** | **OLUMIANT 4 mg** **n=159 (%)** | **OLUMIANT 4 mg + methotrexate n=215 (%)** |
| **Blood and lymphatic system disorders** | | | |
| Anaemia | 2 (1.0) | 2 (1.3) | 4 (1.9) |
| Iron deficiency anaemia | 0 | 1 (0.6) | 3 (1.4) |
| Thrombocytosis | 0 | 3 (1.9) | 2 (0.9) |
| **Cardiac disorders** | | | |
| Coronary artery disease | 0 | 2 (1.3) | 0 |
| **Eye disorders** | | | |
| Vision blurred | 0 | 0 | 3 (1.4) |
| Cataract | 1 (0.5) | 2 (1.3) | 1 (0.5) |
| **Gastrointestinal disorders** | | | |
| Nausea | 11 (5.2) | 7 (4.4) | 16 (7.4) |
| Dyspepsia | 0 | 2 (1.3) | 8 (3.7) |
| Constipation | 2 (1.0) | 1 (0.6) | 5 (2.3) |
| Stomatitis | 1 ( 0.5) | 1 (0.6) | 4 (1.9) |
| Abdominal discomfort | 1 (0.5) | 1 (0.6) | 3 (1.4) |
| Diarrhoea | 9 (4.3) | 3 (1.9) | 3 (1.4) |
| Gastrooesophageal reflux disease | 1 (0.5) | 0 | 3 (1.4) |
| Abdominal pain upper | 4 (1.9) | 3 (1.9) | 1 (0.5) |
| Vomiting | 4 (1.9) | 4 (2.5) | 1 (0.5) |
| **General disorders and administration site conditions** | | | |
| Pyrexia | 4 (1.9) | 1 (0.6) | 6 (2.8) |
| Fatigue | 4 (1.9) | 4 (2.5) | 5 (2.3) |
| Drug intolerance | 2 (1.0) | 2 (1.3) | 0 |
| Oedema peripheral | 1 (0.5) | 3 (1.9) | 0 |
| **Hepatobiliary disorders** | | | |
| Hepatic function abnormal | 4 (1.9) | 1 (0.6) | 6 (2.8) |
| **Infections and infestations** | | | |
| Nasopharyngitis | 11 (5.2) | 11 (6.9) | 14 (6.5) |
| Upper respiratory tract infection | 13 (6.2) | 7 (4.4) | 10 (4.7) |
| Urinary tract infection | 2 (1.0) | 4 (2.5) | 10 (4.7) |
| Pharyngitis | 3 (1.4) | 2 (1.3) | 5 (2.3) |
| Sinusitis | 2 (1.0) | 1 (0.6) | 5 (2.3) |
| Gastroenteritis | 2 (1.0) | 3 (1.9) | 4 (1.9) |
| Influenza | 1 (0.5) | 4 (2.5) | 4 (1.9) |
| Vulvovaginal candidiasis (b) | 1 (0.7) | 0 | 4 (2.6) |
| Bronchitis | 3 (1.4) | 2 (1.3) | 3 (1.4) |
| Cystitis | 0 | 1 (0.6) | 3 (1.4) |
| Herpes zoster | 1 (0.5) | 3 (1.9) | 3 (1.4) |
| Tonsillitis | 1 (0.5) | 2 (1.3) | 1 (0.5) |
| Onychomycosis | 1 (0.5) | 2 (1.3) | 0 |
| **Investigations** | | | |
| Blood creatine phosphokinase increased | 0 | 4 (2.5) | 9 (4.2) |
| Alanine aminotransferase increased | 2 (1.0) | 1 (0.6) | 9 (4.2) |
| Aspartate aminotransferase increased | 1 (0.5) | 0 | 4 (1.9) |
| Blood alkaline phosphatase increased | 1 (0.5) | 1 (0.6) | 4 (1.9) |
| Low density lipoprotein increased | 1 (0.5) | 1 (0.6) | 3 (1.4) |
| Liver function test abnormal | 1 (0.5) | 2 (1.3) | 2 (0.9) |
| Blood cholesterol increased | 0 | 2 (1.3) | 1 (0.5) |
| Platelet count increased | 0 | 2 (1.3) | 1 (0.5) |
| Weight increased | 2 (1.0) | 3 (1.9) | 1 (0.5) |
| White blood cell count increased | 0 | 2 (1.3) | 0 |
| **Metabolism and nutrition disorders** | | | |
| Dyslipidaemia | 2 (1.0) | 2 (1.3) | 6 (2.8) |
| Hyperlipidaemia | 0 | 3 (1.9) | 5 (2.3) |
| Hypercholesterolaemia | 3 (1.4) | 4 (2.5) | 4 (1.9) |
| **Musculoskeletal and connective tissue disorders** | | | |
| Back pain | 3 (1.4) | 2 (1.3) | 5 (2.3) |
| Muscle spasms | 1 (0.5) | 2 (1.3) | 6 (2.8) |
| Osteoarthritis | 0 | 2 (1.3) | 1 (0.5) |
| **Nervous system disorders** | | | |
| Headache | 1 (0.5) | 4 (2.5) | 5 (2.3) |
| Dizziness | 4 (1.9) | 0 | 3 (1.4) |
| Sciatica | 0 | 3 (1.9) | 0 |
| Depression | 3 (1.4) | 6 (3.8) | 1 (0.5) |
| **Reproductive system and breast disorders** | | | |
| Benign prostatic hyperplasia (a) | 0 | 0 | 1 (1.7) |
| **Respiratory, thoracic and mediastinal disorders** | | | |
| Cough | 11 (5.2) | 4 (2.5) | 4 (1.9) |
| Oropharyngeal pain | 1 (0.5) | 2 (1.3) | 2 (0.9) |
| Dyspnea | 4 (1.9) | 2 (1.3) | 0 |
| Rhinorrhea | 0 | 2 (1.3) | 0 |
| **Skin and subcutaneous tissue disorders** | | | |
| Alopecia | 4 (1.9) | 1 (0.6) | 5 (2.3) |
| Acne | 0 | 2 (1.3) | 2 (0.9) |
| Dermatitis contact | 2 (1.0) | 2 (1.3) | 2 (0.9) |
| **Vascular disorders** | | | |
| Hypertension | 5 (2.4) | 1 (0.6) | 9 (4.2) |

1. denominator adjusted because event is specific to males: N=62 (MTX), N=38 (OLUMIANT 4 mg), N=59 (OLUMIANT 4 mg + MTX)
2. denominator adjusted because event is specific to females: N=148 (MTX), N=121 (OLUMIANT4 mg), N=156 (OLUMIANT 4 mg + MTX)

#### Venous thromboembolism

Events of VTE, including DVT and PE, have been reported in clinical trials (see section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE / [Thrombosis](#_Venous_Thromboembolism))

#### Treatment-Naïve Patients

RA-BEGIN evaluated 584 patients with moderate to severe RA who had no or limited exposure to MTX and who were naïve to other DMARDs. The safety profile observed in the OLUMIANT treatment groups was consistent with the overall safety profile of OLUMIANT across all treatment settings. Up to week 52, similar proportions of patients in each of the 3 treatment groups experienced a treatment-emergent adverse event: MTX alone 71.9%, OLUMIANT 4 mg monotherapy 71.1%, and OLUMIANT 4 mg + MTX 77.7%. Likewise, similar proportions of patients experienced serious adverse events (SAEs): MTX alone 9.5%, OLUMIANT 4 mg monotherapy 7.5%, and OLUMIANT 4 mg + MTX 7.9%. Adverse events leading to discontinuation of study drug were most frequent in patients taking baricitinib in combination with MTX: MTX alone 5.2%, OLUMIANT 4 mg monotherapy 5.7%, and OLUMIANT 4 mg +MTX 10.7%. The most common reason for treatment discontinuation was infections or infestations. Three patient deaths were reported during the study, all in the MTX alone group.

#### Methotrexate Inadequate Responders

RA-BEAM evaluated 1305 patients with moderate to severe RA who had had an inadequate response to methotrexate and had not been treated with biologic DMARDs. Patients in this study were randomised to receive placebo, baricitinib or adalimumab. The safety profile observed in the baricitinib treatment groups was consistent with the overall safety profile of baricitinib across all treatment settings. Up to week 24, a higher proportion of patients in the 2 active treatment groups experienced a treatment-emergent adverse event: placebo 60.5%, baricitinib 4 mg 71.3%, and adalimumab 67.9%. Higher proportions of patients experienced serious adverse events (SAEs) in the placebo (4.5%) and baricitinib 4 mg (4.7%) treatment groups compared to adalimumab (1.8%). Adverse events leading to discontinuation of study drug were most frequent in patients taking baricitinib 4 mg (5.1%) compared to placebo (3.5%) and adalimumab (2.1%). The most common reason for treatment discontinuation was infections or infestations.

**Atopic Dermatitis**

A total of 2531 patients were treated with OLUMIANT in clinical studies in atopic dermatitis representing a total of 2247 patient‑years of exposure. Of these 1106 atopic dermatitis patients were exposed to OLUMIANT for at least one year.

Five placebo‑controlled studies were integrated (489 patients on 4 mg once daily, 576 patients on 2 mg once daily and 743 patients on placebo) to evaluate the safety of OLUMIANT in comparison to placebo for up to 16 weeks after treatment initiation.

**Table 4 Adverse Events in Placebo-Controlled Trials: Up to 16 Weeks**

| **System Organ Class/**  **Preferred term** | **Placebo  n=743**  **(%\*)** | **OLUMIANT 2 mg  n= 576**  **(%\*)** | **OLUMIANT 4 mg  n= 489**  **(%\*)** |
| --- | --- | --- | --- |
| **Gastrointestinal disorders** | | | |
| Nausea | 8 (0.8) | 14 (1.8) | 4 (0.8) |
| Abdominal paina | 18 (2.2) | 21 (3.0) | 20 (3.6) |
| **Infections** | | | |
| Upper respiratory tract infectionsb | 124 (14.1) | 114 (16.0) | 103 (17.5) |
| Herpes simplexc | 22 (2.7) | 25 (3.6) | 35 (6.1) |
| Herpes zoster | 3 (0.3) | 6 (0.8) | 0 |
| Urinary tract infection | 8 (0.8) | 9 (1.1) | 11 (2.0) |
| **Investigations** | | | |
| Weight increased | 0 | 3 (0.5) | 4 (0.7) |
| **Nervous system disorders** | | | |
| Headache | 28 (3.3) | 37 (5.9) | 35 (6.3) |
| **Vascular disorders** | | | |
| Deep vein thrombosis | 0 | 0 | 0 |
| **Respiratory, thoracic, mediastinal disorders** | | | |
| Pulmonary embolism | 0 | 0 | 1 (0.1) |
| **Skin and subcutaneous tissue disorders** | | | |
| Rash**d** | 12 (1.2) | 9 (1.3) | 8 (1.3) |
| Acnee | 7 (0.7) | 9 (1.3) | 10 (1.5) |
| Swelling of the facef | 3 (0.3) | 4 (0.5) | 3 (0.6) |
| Urticaria | 4 (0.5) | 3 (0.4) | 2 (0.4) |
| **Laboratory Parameters**g | | | |
| Creatine Phosphokinase >5 x ULN | 14 (1.9) | 14 (2.5) | 16 (3.3) |
| LDL cholesterol ≥130 mg/dL | 34 (6.3) | 52 (12.0) | 48 (13.2) |
| Triglycerides ≥500 mg/dL | 5 (0.8) | 3 (0.6) | 3 (0.7) |
| ALT ≥3 x ULN | 7 (0.8) | 3 (0.4) | 1 (0.2) |
| AST ≥3 x ULN | 7 (0.8) | 5 (0.6) | 3 (0.5) |
| Neutropenia <1000 cells/mm3 | 0 | 1 (0.2) | 1 (0.2) |
| Thrombocytosis >600,000 cells/mm3 | 0 | 7 (1.2) | 3 (0.6) |

\* Study size adjusted percentage.

a Includes abdominal pain, abdominal pain lower, abdominal pain upper.

b Includes acute sinusitis, chronic sinusitis, laryngitis, nasopharyngitis, oropharyngeal pain, pharyngitis, pharyngotonsillitis, rhinitis, sinusitis, tonsillitis, upper respiratory tract infection.

c Includes eczema herpeticum, herpes simplex, Kaposi’s varicelliform eruption, genital herpes, genital herpes simplex, ophthalmic herpes simplex, oral herpes.

d Includes dermatitis, dermatitis allergic, dermatitis contact, drug eruption, eczema, rash, rash maculo-papular, rash pustular.

e Includes acne, acne varioliformis, dermatitis acneiform.

f Includes eye swelling, eyelid oedema, face oedema, lip swelling, swelling face, swelling of eyelid.

g As assessed by measured values within the clinical trial database. Frequencies are based on shifts from pre-treatment to post-treatment (with number at risk as the denominator), except for ALT and AST for which frequencies are based on observed elevation during treatment.

### Adverse Reactions

Adverse Drug Reactions (ADRs) from rheumatoid arthritis and atopic dermatitis clinical studies are presented below by System Organ Class (SOC) and frequency categories, defined using the following convention: very common (≥10%); common (≥1% to <10%), uncommon (≥0.1% to <1%), rare (≥0.01% to <0.1%) or very rare (<0.01%).

**Table 5 Clinical Trial Adverse Reactions**

| **Body system/adverse drug reaction terms** | **Very common**  **≥10%** | **Common**  **≥1% and <10%** | **Uncommon (Infrequent)**  **≥0.1% and <1%** |
| --- | --- | --- | --- |
| **Gastrointestinal disorders** | | | |
| Nausea |  | x |  |
| Abdominal paina |  | x |  |
| **Infections and infestations** | | | |
| Upper respiratory tract infectionsb | x |  |  |
| Herpes simplexc |  | x |  |
| Herpes zoster |  | x |  |
| Urinary tract infection |  | x |  |
| **Investigations** | | | |
| Weight increased |  |  | x |
| **Nervous system disorders** | | | |
| Headache |  | x |  |
| **Vascular disorders** | | | |
| Deep Vein Thrombosis |  |  | x |
| **Respiratory, thoracic, mediastinal disorders** | | | |
| Pulmonary embolism |  |  | x |
| **Skin and subcutaneous tissue disorders** | | | |
| Rashd |  | x |  |
| Acnee |  |  | x |
| Swelling of the facef |  |  | x |
| Urticaria |  |  | x |
| **Laboratory Parametersg** | | | |
| **Clinical Chemistry** | | | |
| Creatine Phosphokinase >5 x ULN |  |  | x |
| LDL cholesterol ≥130 mg/dL (≥3.36 mmol/L) | x |  |  |
| Triglycerides ≥500 mg/dL (≥5.65 mmol/L) |  |  | x |
| ALT ≥3 x ULN |  | x |  |
| AST ≥3 x ULN |  |  | x |
| **Hematology** | | | |
| Neutropenia <1000 cells/mm3 |  |  | x |
| Thrombocytosis >600,000 cells/mm3 |  | x |  |

a Includes abdominal pain, abdominal pain lower, abdominal pain upper.

b Includes acute sinusitis, chronic sinusitis, epiglottitis, laryngitis, nasopharyngitis, oropharyngeal pain, pharyngitis, pharyngotonsillitis, rhinitis, sinobronchitis, sinusitis, tonsillitis, tracheitis, upper respiratory tract infection.

c Includes eczema herpeticum, herpes simplex, Kaposi’s varicelliform eruption, genital herpes, genital herpes simplex, ophthalmic herpes simplex, oral herpes.

d Includes dermatitis, dermatitis allergic, dermatitis contact, drug eruption, eczema, rash, rash erythematous, rash macular, rash maculo-papular, rash pruritic, rash pustular.

e Includes acne, acne varioliformis, dermatitis acneiform.

f Includes eye swelling, eyelid oedema, face oedema, lip swelling, swelling face, swelling of eyelid.

g As assessed by measured values within the clinical trial database. Frequencies are based on shifts from pre-treatment to post-treatment (with number at risk as the denominator), except for ALT and AST for which frequencies are based on observed elevation during treatment.

In patients treated with OLUMIANT in the atopic dermatitis clinical trials, acne and creatine phosphokinase >5x ULN were common. The frequency of herpes zoster was very rare and the frequency of thrombocytosis >600 000 cells/mm3, nausea and ALT ≥3 x ULN was uncommon.

#### Description of selected adverse reactions – Rheumatoid Arthritis

##### Infections

Events related to upper respiratory tract infections, herpes simplex, and herpes zoster were commonly observed during controlled clinical trials. Most infections (as observed in 95% of patients reporting an infection) were mild to moderate in severity.

Serious infections occurred in 1.0% of patients treated with OLUMIANT 4 mg (6 study dataset), 1.3% with OLUMIANT 2 mg (4 study dataset) and 1.0% of patients treated with placebo (6 study dataset) during the initial 12 week period. In RA-BEGIN, the serious infection rate during the 24 week treatment period was 1.3% with OLUMIANT 4 mg monotherapy, 1.9% with OLUMIANT 4 mg plus methotrexate, and 1.4% with methotrexate monotherapy. The most common serious infections were herpes zoster and cellulitis.

##### Nausea

In treatment-naïve patients, through 52 weeks, the frequency of nausea was greater for the combination treatment of methotrexate and OLUMIANT (9.3%) compared to methotrexate alone (6.2%) or OLUMIANT alone (4.4%). Nausea was most frequent during the first 2 weeks of treatment.

*Laboratory Parameters*

##### Neutropenia

In controlled clinical trials, neutrophil counts below 1000 cells/mm3 occurred in 0.3% of patients treated with OLUMIANT 4 mg, 0.6% of patients treated with OLUMIANT 2 mg, and 0% of patients treated with placebo during the initial 12 week treatment period. In RA-BEGIN, decreases in neutrophil counts below 1000 cells/mm3 during the 24 week treatment period did not occur in any patient treated with OLUMIANT 4 mg monotherapy, with OLUMIANT 4 mg plus methotrexate, or with methotrexate monotherapy. In the all-exposure population, the pattern and incidence of decreases in neutrophil counts remained consistent with observations in the controlled periods of the studies.

No association was observed between decreases in neutrophil counts and the occurrence of serious infections. In clinical studies, treatment was interrupted in response to absolute neutrophil counts <1000 cells/mm3 (see section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE ).

##### Thrombocytosis

In controlled clinical trials, increases in platelet counts above 600,000 cells/mm3 occurred in 1.7% of patients treated with OLUMIANT 4 mg, 1.1% of patients treated with OLUMIANT 2 mg, and 0.9% of patients treated with placebo during the 12 week treatment period. In RA-BEGIN, increases in platelet counts above 600,000 cells/mm3 during the 24 week treatment period occurred in 2.6% of patients treated with OLUMIANT 4 mg monotherapy, 1.9% of patients treated with OLUMIANT 4 mg plus methotrexate, and 2.4% of patients treated with methotrexate monotherapy.

In the all exposure population, the pattern and incidence of increases in platelet counts remained consistent with observations in the controlled periods of the studies.

##### Liver Enzyme Elevations

Events of increases in liver enzymes ≥3x ULN were observed in patients treated with OLUMIANT.

ALT elevations ≥3x ULN during the 12 week treatment period occurred in 1.3% of patients treated with OLUMIANT 4 mg, 1.5% with OLUMIANT 2 mg, and 1.0% with placebo.

AST elevations ≥3x ULN during the 12 week treatment period occurred in 0.7% of patients treated with OLUMIANT 4 mg, 1.0% with OLUMIANT 2 mg, and 0.8% of patients receiving placebo.

In RA-BEGIN, ALT and AST elevations ≥3x ULN during the 24 week treatment period occurred in 1.9% and 1.3% of patients treated with OLUMIANT 4 mg monotherapy, 4.7% and 1.9% of patients treated with OLUMIANT 4 mg plus methotrexate, and 1.9% and 0% of patients treated with methotrexate monotherapy (see section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE).

##### Lipids

In controlled clinical trials, OLUMIANT treatment was associated with increases in lipid parameters including total cholesterol, triglycerides, LDL cholesterol, and HDL cholesterol. Elevations were observed at 12 weeks and remained stable thereafter. During 12 weeks of treatment, 33.7% of patients treated with OLUMIANT 4 mg, 20.3 % of patients treated with OLUMIANT 2 mg and 11.3 % of patients treated with placebo developed LDL-C ≥3.36 mmol/L.

Elevations in LDL cholesterol decreased to pre-treatment levels in response to statin therapy.

While increases were observed in LDL and triglycerides, the mean LDL/HDL ratio remained stable. In the all-exposure population, the pattern and incidence of increases in LDL and triglycerides remained consistent with observations in the controlled periods of the studies (see section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE).

##### Creatine Phosphokinase (CPK)

In controlled clinical trials, OLUMIANT treatment was associated with CPK elevations >5x ULN in 0.7% of patients treated with OLUMIANT 4 mg, 0.2% of patients treated with OLUMIANT 2 mg, and 0.3% of patients treated with placebo during the 12 week treatment period. In RA-BEGIN, CPK elevations >5x ULN during the 24 week treatment period occurred in 0.6% of patients treated with OLUMIANT 4 mg monotherapy, 4.3% of patients treated with OLUMIANT 4 mg plus methotrexate, and 0% of patients treated with methotrexate monotherapy.

In the all exposure population, there were no confirmed cases of rhabdomyolysis. The pattern and incidence of increases in CPK remained consistent with observations in the controlled periods of the studies.

#### Description of selected adverse reactions – Atopic Dermatitis

##### Infections

In controlled studies, for up to 16 weeks, the incidence rate of all infections (rate of patients with ≥ 1 event per 100 patient-years of exposure) was 134.5 with OLUMIANT 4 mg compared to 100.3 in the placebo group. Most infections were mild to moderate in severity. Infections were reported in 31.5 %, 29.8 % and 24.2 % of patients up to 16 weeks in the 4 mg, 2 mg and placebo groups, respectively. The percentage of patients reporting infection‑related ADRs for OLUMIANT 4 mg compared to placebo were: Upper respiratory tract infections (17.5 % vs. 14.1%), herpes simplex (6.1 % vs. 2.7 %) and herpes zoster (0 % vs. 0.3 %). In atopic dermatitis clinical studies, the frequency of infections was generally similar to those observed in RA patients except for herpes zoster which was very rare. There were less skin infections requiring antibiotic treatment with OLUMIANT 4 mg (3.4 %) than with placebo (4.4 %). The same percentage of patients with serious infections was observed with OLUMIANT 4 mg and placebo (0.6 %). The overall incidence rate of serious infections with OLUMIANT in the atopic dermatitis clinical trial programme was 2.1 per 100 patient years.

##### Nausea

In atopic dermatitis clinical studies, the frequency of nausea was uncommon with OLUMIANT treatment (0.8%).

##### Neutropenia

In atopic dermatitis controlled studies, for up to 16 weeks, decreases in neutrophil counts below 1 x 109 cells/L occurred in 0.2 % of patients treated with OLUMIANT compared to 0 % of patients treated with placebo. There was no clear relationship between decreases in neutrophil counts and the occurrence of serious infections. However, in clinical studies, treatment was interrupted in response to ANC < 1 x 109 cells/L. The pattern and incidence of decreases in neutrophil counts remained stable at a lower value than baseline over time including in the long-term extension study.

##### Thrombocytosis

In atopic dermatitis controlled studies, for up to 16 weeks, increases in platelet counts above 600 x 109 cells/L occurred in 0.6 % of patients treated with OLUMIANT 4 mg and 0 % of patients treated with placebo. The frequency of thrombocytosis in AD studies was uncommon and lower than that observed in the RA patients.

No association was observed between increased platelet counts and adverse events of a thrombotic nature. The pattern and incidence of increases in platelet counts remained stable at a higher value than baseline over time including in the long term extension study.

##### Liver Enzyme Elevations

In controlled studies, for up to 16 weeks, ALT and AST elevations ≥ 3 x ULN were uncommonly observed in 0.2 % and 0.5 % of patients treated with OLUMIANT 4 mg, compared to 0.8 % and 0.8 % respectively of patients treated with placebo. Most cases of hepatic transaminase elevations were asymptomatic and transient. The pattern and incidence of elevation in ALT/AST remained stable over time including in the long-term extension study.

##### Lipids

In atopic dermatitis clinical trials, OLUMIANT treatment was associated with increases in lipid parameters including total cholesterol, LDL cholesterol, and HDL cholesterol. Elevations were observed at 12 weeks and mean total and LDL cholesterol increased through week 52. There was no increase in the LDL/HDL ratio. No dose‑relationships were observed in controlled studies, for up to 16 weeks for total cholesterol, LDL cholesterol, or HDL cholesterol. There was no increase in triglycerides levels.

*Creatine phosphokinase (CPK)*

In atopic dermatitis controlled studies, for up to 16 weeks, increases in CPK values were common. Significant increases (> 5 x ULN) occurred in a dose-dependent manner in 3.3 %, 2.5 %, and 1.9 % of patients treated with OLUMIANT 4 mg, 2 mg, and placebo, respectively. Most cases were transient and did not require treatment discontinuation.

For atopic dermatitis clinical trials, there were no confirmed cases of rhabdomyolysis. Elevations of CPK were observed at 4 weeks and remained stable at a higher value than baseline thereafter including in the long-term extension study.

## Overdose

Single doses up to 40 mg and multiple doses of up to 20 mg daily for 10 days have been administered in clinical trials without dose-liming toxicity. Pharmacokinetic data of a single dose of 40 mg in healthy volunteers indicate that more than 90% of the administered dose is expected to be eliminated within 24 hours. In case of an overdose, it is recommended that the patient be monitored for signs and symptoms of adverse reactions. Patients who develop adverse reactions should receive appropriate treatment.

For information on the management of overdose, contact the Poison Information Centre on 13 11 26.

# Pharmacological properties

## Pharmacodynamic properties

### Mechanism of action

Janus kinases (JAKs) are enzymes that transduce intracellular signals from cell surface receptors for a number of cytokines and growth factors involved in haematopoiesis, inflammation and immune function. Within the intracellular signalling pathway, JAKs phosphorylate and activate signal transducers and activators of transcription (STATs), which activate gene expression within the cell. OLUMIANT contains baricitinib which modulates these signalling pathways by partially inhibiting JAK1 and JAK2 enzymatic activity, thereby reducing the phosphorylation and activation of STATs.

Baricitinib is a selective and reversible inhibitor of JAK1 and JAK2. In isolated enzyme assays, baricitinib inhibited the activities of JAK1, JAK2, TYK2 and JAK3 with IC50 values of 5.9, 5.7, 53 and >400 nM, respectively.

### Pharmacodynamics

*OLUMIANT inhibition of IL-6 induced STAT3 phosphorylation*

OLUMIANT administration resulted in a dose dependent inhibition of IL-6 induced STAT3 phosphorylation in whole blood from healthy subjects with maximal inhibition observed 2 hours after dosing which returned to near baseline by 24 hours. Similar levels of inhibition were observed using either IL-6 or TPO as the stimulus.

*Immunoglobulins*

Mean serum IgG, IgM, and IgA values decreased by 12 weeks after starting treatment with OLUMIANT, and remained stable through at least 52 weeks. For most patients, changes in immunoglobulins occurred within the normal reference range.

*Lymphocytes*

Mean absolute lymphocyte count increased by 1 week after starting treatment with OLUMIANT, returned to baseline by week 24, and then remained stable through at least 104 weeks. For most patients, changes in lymphocyte count occurred within the normal reference range.

*C-reactive protein*

In patients with rheumatoid arthritis (RA), decreases in serum C-reactive protein (CRP) were observed as early as 1 week after starting treatment with OLUMIANT and were maintained throughout dosing.

*Creatinine*

In atopic dermatitis, baricitinib induced a mean increase in serum creatinine levels (3.5 umol/L) after 12 weeks of treatment, which remained stable thereafter during up to 68 weeks of treatment. This may be due to inhibition of creatinine secretion by baricitinib in the renal tubules. Consequently, estimates of the glomerular filtration rate based on serum creatinine may be slightly reduced, without actual loss of renal function or the occurrence of renal adverse events. In atopic dermatitis, baricitinib was associated with decrease in cystatin C (also used to estimate glomerular filtration rate) of 0.1 mg/L at Week 4, with no further decrease noted up to Week 16.

*Skin biopsies and in vitro skin models*

Elevated pSTAT3 levels are associated with increased inflammation in atopic dermatitis. In lesional skin of patients with atopic dermatitis, OLUMIANT reduced phosphorylated STAT3 (pSTAT3) expression in epidermal keratinocytes at week 4 and week 16 reflecting disease improvement.

In a human skin equivalent model treated with pro-inflammatory cytokines (i.e., IL-4, IL-13, IL-31), OLUMIANT reduced pathological changes consistent with atopic dermatitis, reduced epidermal keratinocyte pSTAT3 expression, and increased the expression of filaggrin, a protein that plays a role in skin barrier function and in the pathogenesis of atopic dermatitis.

### Clinical trials

***Rheumatoid Arthritis***

The efficacy and safety of OLUMIANT was assessed in four randomised, double-blind, multicentre studies in patients with active RA ([Table](#Table4) 6). The patients were diagnosed according to American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) 2010 criteria. Patients over 18 years of age were eligible if at least 6 tender and 6 swollen joints were present at baseline. All patients who completed these studies were eligible to enrol in a long term extension study for up to 4 years continued treatment.

**Table 6 Summary of Clinical Trials**

| **Study name** (duration) | **Population** (Number randomised) | **Treatment arms** | **Summary of key outcome measures** |
| --- | --- | --- | --- |
| RA-BEGIN | MTX-naive1  (584) | OLUMIANT 4 mg QD  OLUMIANT 4 mg QD + MTX  MTX | Primary endpoints:  ACR20 at week 24  Other endpoints:  Physical function (HAQ-DI)  Radiographic progression (mTSS)  Low disease activity and remission (SDAI, DAS28-hsCRP) |
| (52 weeks) | MTX-IR2  (1305) | OLUMIANT 4 mg QD  Adalimumab 40 mg SC Q2W  Placebo  All patients on background MTX | Primary endpoints:  ACR20 at week 12  Other endpoints:  Physical function (HAQ-DI)  Radiographic progression (mTSS)  Low disease activity and remission (SDAI, DAS28-hsCRP)  Morning joint stiffness (duration and severity)  Worst tiredness  Worst joint pain  Radiographic progression (mTSS)  ACR50  ACR70 |
| RA-BEAM | cDMARD-IR3  (684) | OLUMIANT 4 mg QD  OLUMIANT 2 mg QD  Placebo  On background cDMARDs if on stable cDMARD at study entry | Primary endpoints:  ACR20 at week 12  Other endpoints:  Physical function (HAQ-DI)  Radiographic progression (mTSS)  Low disease activity and remission (SDAI,DAS28-hsCRP)  Morning joint stiffness (duration and severity)  Worst tiredness  Worst joint pain |
| (52 weeks) | TNF-IR4  (527) | OLUMIANT 4 mg QD  OLUMIANT 2 mg QD  Placebo  On background cDMARDs | Primary endpoints:  ACR20 at week 12  Other endpoints:  Physical function (HAQ-DI)  Low disease activity and remission (SDAI,DAS28-hsCRP) |
| RA-BUILD | Long Term Extension (2539) | OLUMIANT 4 mg QD  OLUMIANT 2 mg QD | Primary endpoints:  Safety and tolerability assessments  Other Endpoints  Durability of ACR20/50/70 response  Durability of low disease activity or remission (DAS28 hsCRP, DAS28-ESR, SDAI, and CDAI) |

Abbreviations: QD = Once daily; Q2W = Once every 2 weeks; SC = Subcutaneously;

1 Patientswho had received less than 3 doses of Methotrexate (MTX); naïve to other conventional or biologic DMARDs

2 Patientswho had an inadequate response to MTX (+/- other cDMARDs); biologic-naive

3 Patients who had an inadequate response or were intolerant to ≥1 cDMARDs; biologic-naive

4 Patients who had an inadequate response or were intolerant to ≥1 bDMARDs; including at least one TNF inhibitor

**Clinical Response**

In all studies, patients treated with OLUMIANT 4 mg once daily had statistically significantly higher ACR20/50 responses at 12 weeks compared to placebo, methotrexate (MTX) and adalimumab. ACR70 responses in patients treated with OLUMIANT 4 mg once daily were statistically significantly higher at 12 weeks compared to placebo and MTX (see Table 7 and Table 8). Time to onset of efficacy was rapid across measures with greater responses seen as early as week 1. Continued, durable response rates were observed, with ACR20/50/70 responses maintained for at least 2 years including the long-term extension study.

Treatment with OLUMIANT 4 mg, alone or in combination with cDMARDs, resulted in significant improvements in all individual ACR components, including tender and swollen joint counts, patient and physician global assessments, HAQ-DI, pain assessment, and CRP, compared to placebo or MTX monotherapy.

In RA‑BEAM, treatment with OLUMIANT 4 mg resulted in improvements in patient and physician global assessments, HAQ‑DI, pain assessment and CRP at weeks 12, 24, and 52 compared to adalimumab. The percentage of patients who achieved ACR20 response by visit within this study is shown in Figure 1.

In placebo-controlled trials in which MTX was not required, 501 subjects randomised to OLUMIANT 2 mg or 4 mg received MTX as background therapy, and 303 received cDMARDs other than MTX (approximately half with MTX and half without). The most common concomitant disease-modifying antirheumatic drugs (DMARDs) in these subjects were MTX (79% of patients), hydroxychloroquine (19%), leflunomide (11%), and sulphasalazine (9%). No relevant differences regarding efficacy and safety were observed in subgroups defined by types of concomitant DMARDs used in combination with OLUMIANT.

**Remission and Low Disease Activity**

A statistically significantly greater proportion of patients treated with OLUMIANT 4 mg compared to placebo or MTX achieved remission, as defined by Simplified Disease Activity Index (SDAI) ≤3.3, at weeks 12 and 24 (see Tables 9 and 10). Similarly, when defined by Clinical Disease Activity Index (CDAI) ≤2.8, a greater proportion of patients treated with OLUMIANT 4 mg compared to placebo or MTX achieved remission at weeks 12 and 24.

In all 4 completed studies, a higher proportion of patients treated with OLUMIANT 4 mg compared to placebo or MTX achieved low disease activity or remission (Disease Activity Score 28-erythrocyte sedimentation rate [DAS28-ESR] or Disease Activity Score 28-high sensitivity C-reactive protein [DAS28-hsCRP] ≤3.2 and DAS28-ESR or DAS28-hsCRP <2.6) at weeks 12 and 24.

Greater rates of remission compared to placebo were observed as early as week 4. Including data from a long-term extension study, remission and low disease activity rates were maintained for at least 2 years.

**Table 7 ACR Response Rates – Active Comparator Trials**

|  | **Percent of Patients** | | | | | |
| --- | --- | --- | --- | --- | --- | --- |
| **DMARD-naïve** | | | **MTX-IR** | | |
| **Study RA-BEGIN** | | | **Study RA-BEAM** | | |
| **MTX** | **OLUMIANT 4 mg/day** | **OLUMIANT 4 mg/day + MTX** | **Placebo + MTX** | **OLUMIANT 4 mg/day + MTX** | **Adalimumab 40 mg Every Other Week + MTX** |
| **N** | **210** | **159** | **215** | **488** | **487** | **330** |
| **ACR 20** | | | | | | |
| Week 12 | 59 % | 79 %\*\*\* | 77 %\*\*\* | 40 % | 70 %\*\*\*† | 61 %\*\*\* |
| Week 24 | 62 % | 77 %\*\* | 78 %\*\*\* | 37 % | 74 %\*\*\*† | 66 %\*\*\* |
| Week 52 | 56 % | 73 %\*\*\* | 73 %\*\*\* |  | 71 %†† | 62 % |
| **ACR 50** | | | | | | |
| Week 12 | 33 % | 55 %\*\*\* | 60 %\*\*\* | 17 % | 45 %\*\*\*†† | 35 %\*\*\* |
| Week 24 | 43 % | 60 %\*\* | 63 %\*\*\* | 19 % | 51 %\*\*\* | 45 %\*\*\* |
| Week 52 | 38 % | 57 %\*\*\* | 62 %\*\*\* |  | 56 %† | 47 % |
| **ACR 70** | | | | | | |
| Week 12 | 16 % | 31 %\*\*\* | 33 %\*\*\* | 5 % | 19 %\*\*\*† | 13 %\*\*\* |
| Week 24 | 21 % | 42 %\*\*\* | 40 %\*\*\* | 8 % | 30 %\*\*\*† | 22 %\*\*\* |
| Week 52 | 25 % | 42 %\*\*\* | 46 %\*\*\* |  | 37 % | 31 % |

Abbreviations: MTX = methotrexate

\*\* p ≤ 0.01; \*\*\* p ≤ 0.001 vs. placebo (vs. MTX for RA-BEGIN)

† p ≤ 0.05; †† p ≤ 0.01;

Table 8 ACR Response Rates – Placebo Controlled Trials

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Percent of Patients** | | | | | |
| **cDMARD-IR** | | | **TNFi-IR** | | |
| **Study RA-BUILD** | | | **Study RA-BEACON** | | |
| **Placebo + cDMARDs** | **OLUMIANT 2 mg/day + cDMARDs** | **OLUMIANT 4 mg/day + cDMARDs** | **Placebo + cDMARDs** | **OLUMIANT 2 mg/day + cDMARDs** | **OLUMIANT 4 mg/day + cDMARDs** |
| **N** | **228** | **229** | **227** | **176** | **174** | **177** |
| **ACR 20** | | | | | | |
| Week 12 | 39 % | 66 %\*\*\* | 62 %\*\*\* | 27 % | 49 %\*\*\* | 55 %\*\*\* |
| Week 24 | 42 % | 61 %\*\*\* | 65 %\*\*\* | 27 % | 45 %\*\*\* | 46 %\*\*\* |
| **ACR 50** | | | | | | |
| Week 12 | 13 % | 34 %\*\*\* | 33 %\*\*\* | 8 % | 20 %\*\* | 28 %\*\*\* |
| Week 24 | 21 % | 41 %\*\*\* | 44 %\*\*\* | 13 % | 23 %\* | 29 %\*\*\* |
| **ACR 70** | | | | | | |
| Week 12 | 3 % | 18 %\*\*\* | 18 %\*\*\* | 2 % | 13 %\*\*\* | 11 %\*\* |
| Week 24 | 8 % | 25 %\*\*\* | 24 %\*\*\* | 3 % | 13 %\*\*\* | 17 %\*\*\* |

\* p ≤ 0.05; \*\* p ≤ 0.01; \*\*\* p ≤ 0.001 vs. placebo

**Table 9 Low Disease Activity and Clinical Remission – Active Comparator Trials**

|  | **Percent of Patients** | | | | | |
| --- | --- | --- | --- | --- | --- | --- |
| **DMARD-naïve** | | | **MTX-IR** | | |
| **Study RA-BEGIN** | | | **Study RA-BEAM** | | |
| **MTX** | **OLUMIANT 4 mg/day** | **OLUMIANT 4 mg/day + MTX** | **Placebo + MTX** | **OLUMIANT 4** **mg/day + MTX** | **Adalimumab 40 mg Every Other Week + MTX** |
| **N** | **210** | **159** | **215** | **488** | **487** | **330** |
| **SDAI ≤3.3a** | | | | | | |
| Week 12 | 6 % | 14 %\* | 20 %\*\*\* | 2 % | 8 %\*\*\* | 7 %\*\*\* |
| Week 24 | 10 % | 22 %\*\* | 23 %\*\*\* | 3 % | 16 %\*\*\* | 14 %\*\*\* |
| Week 52 | 13 % | 25 %\*\* | 30 %\*\*\* |  | 23 % | 18 % |
| **CDAI ≤2.8b** | | | | | | |
| Week 12 | 7 % | 14 %\* | 19 %\*\*\* | 2 % | 8 %\*\*\* | 7 %\*\* |
| Week 24 | 11 % | 21 %\*\* | 22 %\*\* | 4 % | 16 %\*\*\* | 12 %\*\*\* |
| Week 52 | 16 % | 25 %\* | 28 %\*\* |  | 22 % | 18 % |
| **DAS28-hsCRP ≤3.2c** | | | | | | |
| Week 12 | 30 % | 47 %\*\*\* | 56 %\*\*\* | 14 % | 44 %\*\*\*†† | 35 %\*\*\* |
| Week 24 | 38 % | 57 %\*\*\* | 60 %\*\*\* | 19 % | 52 %\*\*\* | 48 %\*\*\* |
| Week 52 | 38 % | 57 %\*\*\* | 63 %\*\*\* |  | 56 %† | 48 % |
| **DAS28-ESR ≤3.2d** | | | | | | |
| Week 12 | 15 % | 21 % | 34 %\*\*\* | 7 % | 24 %\*\*\* | 21 %\*\*\* |
| Week 24 | 23 % | 36 %\*\* | 39 %\*\*\* | 10 % | 32 %\*\*\* | 34 %\*\*\* |
| Week 52 | 27 % | 36 % | 45 %\*\*\* |  | 39 % | 36 % |
| **HAQ-DI Minimum Clinically Important Difference (decrease in score of ≥0.30):e** | | | | | | |
| Week 12 | 60 % | 81 %\*\*\* | 77 %\*\*\* | 46 % | 68 %\*\*\* | 64 %\*\*\* |
| Week 24 | 66 % | 77 %\* | 74 % | 37 % | 67 %\*\*\*† | 60 %\*\*\* |
| Week 52 | 53 % | 65 %\* | 67 %\*\* |  | 61 % | 55 % |

\* p ≤ 0.05; \*\* p ≤ 0.01; \*\*\* p ≤ 0.001 vs. placebo (vs. MTX for RA-BEGIN)

† p ≤ 0.05; †† p ≤ 0.01; vs. adalimumab

a Simplified Disease Activity Index

b Clinical Disease Activity Index

c Disease Activity Score 28-high sensitivity C-reactive protein

d Disease Activity Score 28-erythrocyte sedimentation rate

e Health Assessment Questionnaire–Disability Index

**Table 10 Low Disease Activity and Clinical Remission – Placebo Controlled Trials**

|  | **Percent of Patients** | | | | | |
| --- | --- | --- | --- | --- | --- | --- |
| **cDMARD-IR** | | | **TNFi-IR** | | |
| **Study RA-BUILD** | | | **Study RA-BEACON** | | |
| **Placebo + cDMARDs** | **OLUMIANT 2 mg/day + cDMARDs** | **OLUMIANT 4 mg/day + cDMARDs** | **Placebo + cDMARDs** | **OLUMIANT 2 mg/day + cDMARDs** | **OLUMIANT 4** **mg/day + cDMARDs** |
| **N** | **228** | **229** | **227** | **176** | **174** | **177** |
| **SDAI ≤3.3a** | | | | | | |
| Week 12 | 1 % | 9 %\*\*\* | 9 %\*\*\* | 2 % | 2 % | 5 % |
| Week 24 | 4 % | 17 %\*\*\* | 15 %\*\*\* | 2 % | 5 % | 9 %\*\* |
| **CDAI ≤2.8b** | | | | | | |
| Week 12 | 2 % | 10 %\*\*\* | 9 %\*\*\* | 2 % | 3 % | 6 % |
| Week 24 | 4 % | 15 %\*\*\* | 15 %\*\*\* | 3 % | 5 % | 9 %\* |
| **DAS28-hsCRP ≤3.2c** | | | | | | |
| Week 12 | 17 % | 36 %\*\*\* | 39 %\*\*\* | 9 % | 24 %\*\*\* | 32 %\*\*\* |
| Week 24 | 24 % | 46 %\*\*\* | 52 %\*\*\* | 11 % | 20 %\* | 33 %\*\*\* |
| **DAS28-ESR ≤3.2d** | | | | | | |
| Week 12 | 7 % | 21 %\*\*\* | 22 %\*\*\* | 4 % | 13 %\*\* | 12 %\*\* |
| Week 24 | 10 % | 29 %\*\*\* | 32 %\*\*\* | 7 % | 11 % | 17 %\*\* |
| **HAQ-DI Minimum Clinically Important Difference (decrease in score of ≥0.30):e** | | | | | | |
| Week 12 | 44 % | 60 %\*\*\* | 56 %\*\* | 35 % | 48 %\* | 54 %\*\*\* |
| Week 24 | 37 % | 58 %\*\*\* | 55 %\*\*\* | 24 % | 41 %\*\*\* | 44 %\*\*\* |

\* p ≤ 0.05; \*\* p ≤ 0.01; \*\*\* p ≤ 0.001 vs. placebo

a Simplified Disease Activity Index


b Clinical Disease Activity Index

c Disease Activity Score 28-high sensitivity C-reactive protein

d Disease Activity Score 28-erythrocyte sedimentation rate

e Health Assessment Questionnaire–Disability Index

### Figure 1 Percent of Patients Achieving ACR20 in RA-BEAM (mITT, using NRI)



ACR20 ≥ 20% improvement in American College of Rheumatology criteria


N = number of modified intent-to-treat (mITT) patients

NRI = non-responder imputation.

**Physical Function Response and Health-Related Outcomes**

Treatment with OLUMIANT 4 mg, alone or in combination with cDMARDs, resulted in a statistically significant improvement in physical function compared to placebo and MTX as measured by HAQ-DI, at 12, 24 and 52 weeks. Improvements with OLUMIANT 4 mg treatment were also shown versus adalimumab at these time points. The proportion of patients achieving a clinically significant improvement (HAQ-DI improvement from baseline ≥0.30) was also higher with OLUMIANT compared to placebo or MTX at week 12 (Table 9 and 10). Improvements were seen as early as Week 1 and, in RA-BEGIN and RA-BEAM (see Figure 2), these were maintained for up to 52 weeks.

Figure 2 Change in HAQ-DI from Baseline to Week 52 in RA-BEAM (mITT, using **mLOCF)**



HAQ-DI = Health Assessment Questionnaire-Disability Index

N = number of modified intent-to-treat (mITT) patients

mLOCF = modified last observation carried forward

Treatment with OLUMIANT 4 mg, alone or in combination with cDMARDs, resulted in a significant improvement in pain compared to all comparators (placebo, MTX, and adalimumab), as measured on a 0-100 visual analogue scale, at 12 weeks. Greater pain reduction was seen as early as Week 1 and, in RA-BEGIN and RA‑BEAM, this was maintained for up to 52 weeks.

In RA-BEAM and RA-BUILD, treatment with OLUMIANT 4 mg resulted in an improvement in the mean duration and severity of morning joint stiffness, and mean worst tiredness, compared to placebo or adalimumab as assessed using daily electronic patient diaries for 12 weeks.

In all studies, OLUMIANT-treated patients reported improvements in patient-reported quality of life, as measured by the Short Form (36) Health Survey (SF36) Physical Component Score, fatigue, as measured by the Functional Assessment of Chronic Illness Therapy-Fatigue score (FACIT-F) and work productivity, as measured by the Work Productivity and Activity Impairment Questionnaire: Rheumatoid Arthritis (WPAI‑RA)

**Radiographic Response**

The effect of OLUMIANT on progression of structural joint damage was evaluated radiographically in RA-BEGIN, RA-BEAM, and RA-BUILD and assessed using the modified Total Sharp Score (mTSS) and its components, the erosion score and joint space narrowing score.

Treatment with OLUMIANT 4 mg resulted in a statistically significant inhibition of progression of structural joint damage (Table 11). Analyses of erosion and joint space narrowing scores were consistent with the overall scores. The proportion of patients with no radiographic progression (mTSS change ≤0) was statistically significantly higher with OLUMIANT 4 mg compared to placebo at week 24.

**Table 11 Radiographic Changes**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Study | **RA-BEGIN**  MTX-naïve patients | | | **RA-BEAM**  MTX-IR patients | | | **RA-BUILD**  cDMARD-IR patients | | |
| Treatment group | MTX | OLU 4 mg | OLU 4 mg  + MTX | PBO | OLU 4 mg | ADA 40 mg Q2W | PBO | OLU 2 mg | OLU 4 mg |
| **N** | 210 | 159 | 215 | 488 | 487 | 330 | 228 | 229 | 227 |
| **Modified Total Sharp Score, mean change from baseline:** | | | | | | | | | |
| Week 24 | 0.61 | 0.39 | 0.29\* | 0.90 | 0.41\*\*\* | 0.33\*\*\* | 0.70 | 0.33\* | 0.15\*\* |
| Week 52 | 1.02 | 0.80 | 0.40\*\* |  | 0.71 | 0.60 |  |  |  |
| **Erosion Score, mean change from baseline:** | | | | | | | | | |
| Week 24 | 0.47 | 0.33 | 0.26\* | 0.61 | 0.29\*\*\* | 0.24\*\*\* | 0.47 | 0.30 | 0.11\*\* |
| Week 52 | 0.81 | 0.55 | 0.34\*\* |  | 0.51 | 0.42\*\*\* |  |  |  |
| **Joint Space Narrowing Score, mean change from baseline:** | | | | | | | | | |
| Week 24 | 0.14 | 0.06 | 0.03 | 0.29 | 0.12\*\* | 0.10\*\* | 0.23 | 0.03\* | 0.04\* |
| Week 52 | 0.21 | 0.25 | 0.06 |  | 0.21 | 0.19 |  |  |  |
| **Proportion of patients with no radiographic progressiona:** | | | | | | | | | |
| Week 24 | 68 % | 76 % | 81 %\*\* | 70 % | 81 %\*\*\* | 83 %\*\*\* | 74 % | 72 %\* | 80 %\*\* |
| Week 52 | 66 % | 69 % | 80 %\*\* |  | 79 % | 81 % |  |  |  |

Abbreviations: ADA = adalimumab; MTX = methotrexate; OLU = Olumiant; PBO = Placebo ; MTX-IR = methotrexate inadequate responders; cDMARD -IR = conventional disease-modifying antirheumatic drug inadequate responders.

a No progression defined as mTSS change ≤ 0.

\* p ≤ 0.05; \*\* p ≤ 0.01; \*\*\* p ≤ 0.001 vs. placebo (vs. MTX for study RA-BEGIN)

**OLUMIANT 4 mg vs. 2 mg**

In clinical trials that included doses of 2 mg and 4 mg OLUMIANT once daily (RA-BUILD and RA-BEACON), efficacy on signs and symptoms was demonstrated with both doses. However, more consistent improvements in remission and low disease activity were seen with the 4 mg dose. The differences were most notable in the bDMARD-IR population (RA-BEACON), in which statistically significant improvements in the ACR components of swollen joint count, tender joint count and ESR were shown for OLUMIANT 4 mg compared to placebo at week 24 but not for OLUMIANT 2 mg compared to placebo. In addition, onset of efficacy was fastest and the effect size was generally largest for the 4 mg dose groups compared to 2 mg.

In a long-term extension study, patients from RA-BEAM, RA-BUILD and RA-BEACON who achieved sustained low disease activity or remission (CDAI≤10) after at least 15 months of treatment with OLUMIANT 4 mg once daily (N = 502) were re-randomised 1:1 in a double-blind manner to continue 4 mg once daily or reduce dose to 2 mg once daily. A down titration in the baricitinib dose was associated with a significant reduction in efficacy. The majority of patients maintained low disease activity or remission based on CDAI score:

* At week 12: 234/251 (93%) continuing 4 mg vs 207/251 (82%) reduced to 2 mg (p ≤ 0.001)
* At week 24: 163/191 (85%) continuing 4 mg vs 144/189 (76%) reduced to 2 mg (p ≤ 0.05)
* At week 48: 57/73 (78%) continuing 4 mg vs 51/86 (59%) reduced to 2 mg (p ≤ 0.05)

The majority of patients who lost their low disease activity or remission status after dose reduction could regain disease control after the dose was returned to 4 mg.

**OLUMIANT Used as Monotherapy or in Combination with Methotrexate**

In RA-BEGIN, OLUMIANT 4 mg monotherapy was statistically significantly superior to methotrexate monotherapy with respect to ACR20 response rates at 24 weeks (see Table 12). Combination of OLUMIANT 4 mg with methotrexate therapy was associated with larger improvements in inflammation related measures, including ESR; correspondingly, although most patients did not exhibit radiographic progression across the treatment groups, the lowest radiographic progression rates were seen in the combination group. OLUMIANT 2 mg was not studied in this trial.

In RA-BUILD, treatment effects compared to placebo were robust whether OLUMIANT was used as monotherapy, in combination with methotrexate, or in combination with cDMARDs other than methotrexate.

**DMARD-Naïve RA Patients**

RA-BEGIN, a 52-week study with the planned primary analysis at week 24, evaluated 584 DMARD-naïve adult patients with moderate to severe, active RA (mean disease duration was 1.3 years) and indicators of poor prognosis, such as elevated inflammatory markers (CRP) and the presence of rheumatoid factor or anti-cyclic citrullinated peptides. This study evaluated the efficacy of OLUMIANT 4 mg monotherapy, OLUMIANT 4 mg + MTX, and MTX alone in improving the signs and symptoms of RA, physical function, and rate of progression of joint damage. The primary endpoint was the proportion of patients achieving ACR20 at week 24.

A significantly higher proportion of patients in the OLUMIANT 4 mg and OLUMIANT 4 mg + MTX groups compared to MTX alone achieved an ACR20 response at week 24: 77% versus 62% (p = 0.003) for OLUMIANT 4 mg monotherapy and 78% versus 62% (p ≤ 0.001) for OLUMIANT 4 mg + MTX. The OLUMIANT 4 mg monotherapy and OLUMIANT 4 mg + MTX groups also showed statistically significant improvement compared to MTX alone across the key secondary endpoints at week 24 and 52, including ACR20, SDAI remission, and change from baseline in DAS28-hsCRP and HAQ-DI. At 52 weeks, the OLUMIANT 4 mg + MTX group showed statistically significant improvement compared to MTX as measured by mTSS and a numerically greater response in the OLUMIANT 4 mg monotherapy group compared with MTX alone. The efficacy results from RA-BEGIN are shown in Table 12.

**Table 12 Efficacy Results for RA-BEGIN in DMARD-naïve Patients**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  |  | **OLUMIANT 4 mg/day** | **OLUMIANT 4 mg/day + MTX** | **MTX** |
|  |  |  | **N=159** | **N=215** | **N=210** |
| **Primary Endpoint** | | | | | |
| ACR20 (%) | Week 24 |  | 77\*\* | NA | 62 |
| **Key Secondary Endpoints** | | | | | |
| ACR (%) | Week 24 | ACR20 | NA | 78\*\*\* | 62 |
|  |  | ACR50 | 60\*\* | 63\*\*\* | 43 |
|  |  | ACR70 | 42\*\*\* | 40\*\*\* | 21 |
|  | Week 52 | ACR20 | 73\*\*\* | 73\*\*\* | 56 |
|  |  | ACR50 | 57\*\*\* | 62\*\*\* | 38 |
|  |  | ACR70 | 42\*\*\* | 46\*\*\* | 25 |
| HAQ-DI (mean change from baseline) | | | | | |
|  | Week 24 |  | -1.04\*\*\* | -1.03\*\*\* | -0.74 |
|  | Week 52 |  | -0.99\*\*\* | -1.06\*\*\* | -0.71 |
| DAS28-hsCRP <2.6 response (%) | | | | | |
|  | Week 24 |  | 40\*\*\* | 40\*\*\* | 24 |
|  | Week 52 |  | 44\*\*\* | 49\*\*\* | 24 |
| DAS28-hsCRP ≤3.2 response (%) | | | | | |
|  | Week 24 |  | 57\*\*\* | 60\*\*\* | 38 |
|  | Week 52 |  | 57\*\*\* | 63\*\*\* | 38 |
| SDAI remission ≤3.3 (%) | | | | | |
|  | Week 24 |  | 22\*\* | 23\*\*\* | 10 |
|  | Week 52 |  | 25\*\* | 30\*\*\* | 13 |
| **Radiographic Endpoints (mean change from baseline)** | | | | | |
|  | Week 52 | mTSS | 0.80 | 0.40\*\* | 1.02 |
|  |  | Erosion Score | 0.55 | 0.34\*\* | 0.81 |
|  |  | JSN | 0.25 | 0.06 | 0.21 |
| Radiographic non-progression (%)  (change from baseline in mTSS ≤0) | | | 69 | 80\*\* | 66 |

Abbreviations: NA = Not applicable; MTX = methotrexate; ACR20 = 20% improvement in American College of Rheumatology criteria; ACR50 = 50% improvement in American College of Rheumatology criteria; ACR70 = 70% improvement in American College of Rheumatology criteria; HAQ-DI = Health Assessment Questionnaire-Disability Index; DAS28-hsCRP = Disease Activity Score 28-high-sensitivity C-reactive protein; SDAI = Simplified Disease Activity Index; mTSS = modified Total Sharp Score

\*\* p ≤ 0.01; \*\*\* p ≤ 0.001 vs. MTX.

***Atopic Dermatitis***

The efficacy and safety of OLUMIANT as monotherapy or in combination with topical corticosteroids (TCS) were assessed in 3 Phase III randomised, double‑blind, placebo-controlled, 16 week studies (BREEZE-AD1, -AD2 and -AD7). The outcomes of the primary and key secondary endpoints from these studies were adjusted for multiplicity.

The studies included 1568 patients with moderate to severe atopic dermatitis defined by Investigator's Global Assessment (IGA) score ≥ 3, an Eczema Area and Severity Index (EASI) score ≥ 16, and a body surface area (BSA) involvement of ≥ 10 %. Eligible patients were over 18 years of age and had previous inadequate response or were intolerant to topical medication. Patients were permitted to receive rescue treatment (which included topical or systemic therapy), at which time they were considered non-responders. All patients who completed these studies were eligible to enrol in a long term extension study (BREEZE AD-3) for up to 2 years of continued treatment.

***Clinical Study Summary***

**Table 13 Summary of Clinical Trial**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Study Name** (Duration) | **No. of Patients Treated**(N) | **Background Treatment**a | **Treatment arms (QD)** | **Outcome Measures** |
| BREEZE AD-1 (16 weeks) | 624 | None | OLU 4 mg  OLU 2 mg  OLU 1 mg  Placebo | **Primary endpoint**   * IGA 0 or 1b at week 16   **Key secondary endpoint**   * Improvement of ≥ 75% or 90 % in Eczema Area and Severity Index from baseline (EASI 75, 90) * Improvement of ≥ 75 % in SCORing Atopic Dermatitis (SCORAD) scale * Itch Numerical Rating Scale (NRS) ≥ 4-point improvement * Impact of itch on sleep as measured by Atopic Dermatitis Sleep Scale (ADSS) * Skin pain severity as measured by Skin Pain NRS   **Other secondary endpoints**   * EASI 50 * Itch Numerical Rating Scale (NRS) change from baseline * Patient-Oriented Eczema Measure (POEM) * Dermatology Life Quality Index (DLQI) * Hospital Anxiety and Depression Scale (HADS) |
| BREEZE AD-2 (16 weeks) | 615 | None |
| BREEZE AD-7 (16 weeks) | 329 | TCS; TCI as needed | OLU 4 mg  OLU 2 mg  Placebo |

OLU=OLUMIANT; QD = Once daily; TCI = Topical Calcineurin Inhibitor; TCS = Topical Corticosteroid

The primary and key secondary endpoints were adjusted for multiple comparisons. Other secondary endpoints were not adjusted for multiple comparisons.

a Patients used emollients throughout the study.

b Investigators Global Assessment score of 0 (“clear”) or 1 (“almost clear”) with a reduction of ≥2 points on a 5-point severity scale of 0 to 4.

*Baseline Characteristics*

In the monotherapy studies (BREEZE-AD1 and BREEZE-AD2), across all treatment groups, the mean age was 35.2, the mean weight was 73.3 kg, 37.7 % were female, 63.5 % were Caucasian, 30 % were Asian and 0.2 % were black. In these studies, 54 % of patients had a baseline IGA score of 3 (moderate AD), 46 % of patients had a baseline IGA of 4 (severe AD) and 59.9 % of patients had received prior systemic treatment for atopic dermatitis. The baseline mean EASI score was 32.2, the baseline mean BSA score was 52.3, the baseline weekly averaged pruritus NRS was 6.6, the baseline mean SCORAD score was 67.8, the baseline mean POEM score was 20.6, the baseline mean DLQI was 14.0, the baseline mean HADS depression score was 5.0, and the baseline mean HADS anxiety score was 6.1.

In the combination TCS study (BREEZE-AD7), across all treatment groups, the mean age was 33.8, the mean weight was  72.9 kg, 34.3 % were female, 45.6 % were Caucasian, 51.1 % were Asian. In this study, 54.9 % of patients had a baseline IGA score of 3, 45.1 % of patients had a baseline IGA of 4 and 66.4 % of patients received prior systemic treatment. The baseline mean EASI score was 29.6, the baseline mean BSA score was 50.3, the baseline weekly averaged pruritus NRS was 7.1, the baseline mean SCORAD score was 67.2, the baseline mean POEM score was 21.1, the baseline mean DLQI was 14.9, the baseline mean HADS depression score was 5.5, and the baseline mean HADS anxiety score was 6.6.

*Clinical Response*

*16-week Monotherapy Studies (BREEZE-AD1 and BREEZE-AD2)*

In BREEZE-AD1 and BREEZE-AD2, a significantly greater proportion of patients randomised to OLUMIANT 4 mg achieved an IGA 0 or 1 response, EASI75, or an improvement of ≥ 4 points on the Itch NRS compared to placebo at week 16 (Table 14).

A significantly greater proportion of patients randomised to OLUMIANT 4 mg achieved a rapid improvement in the Itch NRS compared to placebo (defined as ≥ 4‑point improvement as early as Day 2; p ≤0.05). The improvement in Itch NRS occurred in conjunction with the improvement of objective skin signs of atopic dermatitis.

Figures 3 and 4 respectively show the mean percent change from baseline in EASI and in Itch NRS, up to week 16.

Treatment effects in subgroups (weight, age, gender, race, disease severity and previous treatment, including immunosuppressants) in BREEZE-AD1 and BREEZE-AD2 were consistent with the results in the overall study population.

**Table 14 Efficacy of OLUMIANT monotherapy at week 16 (FASa)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Study** | **BREEZE- AD1** | | | **BREEZE-AD2** | | |
| Treatment  Group | PBO | OLU  2 mg | OLU  4 mg | PBO | OLU  2 mg | OLU  4 mg |
| N | N = 249 | N = 123 | N = 125 | N = 244 | N = 123 | N = 123 |
| IGA 0 or 1,  % respondersb, c | 4.8 % | 11.4 %\* | 16.8 %\*\*\* | 4.5 % | 10.6 %\* | 13.8 %\*\*\* |
| EASI-50,  % respondersc, g | 15.3 % | 30.1 %\*\*\* | 41.6 %\*\*\* | 12.3 % | 27.6 %\*\*\* | 29.3 %\*\*\* |
| EASI-75,  % respondersc | 8.8 % | 18.7 %\*\* | 24.8 %\*\*\* | 6.1 % | 17.9 %\*\*\* | 21.1 %\*\*\* |
| EASI-90,  % respondersc | 4.8 % | 10.6 %\*f | 16.0 %\*\*\* | 2.5 % | 8.9 %\*\* | 13.0 %\*\*\* |
| SCORAD75,  % respondersc | 1.2 % | 7.3 %\*\*f | 10.4 %\*\*\* | 1.6 % | 7.3 %\*\* | 11.4 %\*\*\* |
| Itch NRS (≥ 4 point improvement), % respondersc, d | 7.2 % | 12.0 % | 21.5 %\*\*\* | 4.7 % | 15.1 %\*\* | 18.7 %\*\*\* |
| BSA change from baseline, LS mean (SE)e, g | -14.80 %  (1.82) | -20.14 %  (2.16) | -25.96 %\*\*\*  (1.93) | -12.82 %  (2.07) | -22.12 %\*\*  (2.37) | -23.98 %\*\*\*  (2.17) |

OLU = OLUMIANT; PBO = Placebo

\*p  ≤ 0.05; \*\*p ≤ 0.01; \*\*\*p ≤ 0.001 vs placebo.

a Full analysis set (FAS) including all randomised patients.

b Responder was defined as a patient with IGA 0 or 1 (“clear” or “almost clear”) with a reduction of ≥ 2 points on 0-4 IGA scale.

c Non-Responder Imputation: Patients who received rescue treatment or with missing data were considered as non-responders.


d Results shown in subset of patients eligible for assessment (patients with itch NRS ≥ 4 at baseline).

e Data collected after rescue therapy or after permanent study drug discontinuation were considered missing.  LS means are from MMRM analyses which incorporates multiple imputation for missing data.

f Not statistically significant after adjustment for multiple comparisons.

g Endpoint was not adjusted for multiplicity.


**Figure 3. Mean percent change from baseline in EASI in BREEZE-AD1and BREEZE-AD2(FAS)a**



LS = Least squares; \*\*p≤0.01, \*\*\*p≤0.001 versus placebo

a Full analysis set (FAS) including all patients randomised. Data collected after rescue therapy or after permanent study drug discontinuation were considered missing.  LS means are from MMRM analyses which incorporates multiple imputation for missing data.

**Figure 4. Mean percent change from baseline in Itch NRS in BREEZE-AD1and BREEZE-AD2(FAS)a**



LS = Least squares; \*p≤0.05,\*\*p≤0.01, \*\*\*p≤0.001 vs placebo

a Full analysis set (FAS) including all patients randomised. Data collected after rescue therapy or after permanent study drug discontinuation were considered missing.  LS means are from MMRM analyses which incorporates multiple imputation for missing data.

*16-Week combination TCS Study (BREEZE-AD7)*

In BREEZE-AD7, a significantly greater proportion of patients randomised to OLUMIANT 4 mg + TCS achieved an IGA 0 or 1 response, EASI-75, or an improvement of ≥ 4 points on the itch NRS compared to placebo at week 16 (Table 15).

A significantly greater proportion of patients randomised to OLUMIANT 4 mg achieved a rapid improvement in the Itch NRS compared to placebo (defined as ≥ 4‑point improvement as early as Week 2; p <0 .001). The improvement in Itch NRS occurred in conjunction with the improvement of objective skin signs of atopic dermatitis.

Figures 5 and 6 respectively show the mean percent change from baseline in EASI and in Itch NRS, up to week 16.

Treatment effects in subgroups (weight, age, gender, race, disease severity and previous treatment, including immunosuppressants) in BREEZE-AD7 were consistent with the results in the overall study population.

**Table 15 Efficacy of OLUMIANT in combination with TCSa at week 16 (FAS) b**

|  |  |  |  |
| --- | --- | --- | --- |
| Study | **BREEZE- AD7** | | |
| Treatment  group | PBOa | OLU 2 mg a | OLU 4 mg a |
| N | 109 | 109 | 111 |
| IGA 0 or 1,  % respondersc, d | 14.7 % | 23.9 % | 30.6 %\*\* |
| EASI-50,  % respondersd, h | 41.3 % | 64.2 %\*\*\* | 70.3 %\*\*\* |
| EASI-75,  % respondersd | 22.9 % | 43.1 %\*\*g | 47.7 %\*\*\* |
| EASI-90,  % respondersd | 13.8 % | 16.5 % | 24.3 %\*g |
| SCORAD75,  % respondersd | 7.3 % | 11.0 % | 18.0 %\*g |
| Itch NRS (≥ 4-point improvement), % respondersd, e | 20.2 % | 38.1 %\*\*g | 44.0 %\*\*\* |
| BSA change from baseline, LS mean (SE)f, h | -18.03 %  (1.89) | -27.00 %\*\*\*  (1.83) | 29.73 %\*\*\*  (1.81) |

OLU = Olumiant; PBO = Placebo

\*p ≤ 0.05; \*\*p ≤ 0.01; \*\*\*p ≤ 0.001 vs placeboa All patients were on background topical corticosteroids therapy and patients were permitted to use topical calcineurin inhibitors.

b Full analysis set (FAS) includes all randomised patients.

c Responder was defined as a patient with IGA 0 or 1 (“clear” or “almost clear”) with a reduction of

≥ 2 points on a 0-4 IGA scale.

d Non-Responder Imputation: Patients who received rescue treatment or with missing data were considered as non-responders.


e Results shown in subset of patients eligible for assessment (patients with itch NRS ≥ 4 at baseline)

f Data collected after rescue therapy or after permanent study drug discontinuation were considered missing.  LS means are from MMRM analyses which incorporates multiple imputation for missing data.

g Not statistically significant after adjustment for multiple comparisons.

h Endpoint was not adjusted for multiplicity.


**Figure 5. Mean percent change from baseline in EASI in BREEZE-AD7(FAS)a**



LS = Least squares; \*p≤0.05 \*\*p≤0.01, \*\*\*p≤0.001 vs placebo

a Full analysis set (FAS) including all patients randomised. Data collected after rescue therapy or after permanent study drug discontinuation are considered missing.  LS means are from MMRM analyses which incorporates multiple imputation for missing data.

**Figure 6. Mean percent change from baseline in itch NRS in BREEZE-AD7 (FAS)a**




LS = Least squares; p≤0.05,\*\*p≤0.01, \*\*\*p≤0.001 vs placebo

a Full analysis set (FAS) including all patients randomised. Data collected after rescue therapy or after permanent study drug discontinuation are considered missing.  LS means are from MMRM analyses which incorporates multiple imputation for missing data.

*Maintenance and Durability of Response*

To evaluate maintenance of response, subjects treated with OLUMIANT for 16 weeks in BREEZE-AD1 and BREEZE-AD2 were eligible to enrol in a long term extension study BREEZE-AD3 to an additional 36-weeks of treatment, for a cumulative 52-week study treatment. Continued, durable response was observed. Figure 7 shows the percentage of patients with EASI 75 from baseline in BREEZE-AD3 up to week 52.

**Figure 7. EASI 75 Persistence over time for OLUMIANT 4 mg in BREEZE-AD3 up to Week 52a**



a Non-Responder Imputation was used. Patients who received rescue treatment (other than topical treatment) or with missing data were considered as non-responders. Data for week 52 are shown for the evaluable population.

*Quality of Life/Patient-Reported Outcomes in Atopic Dermatitis*

In both monotherapy studies (BREEZE-AD1 and BREEZE-AD2) and in the comcomitant TCS study (BREEZE-AD7), OLUMIANT 4 mg significantly improved patient-reported outcomes, including itch, sleep (as measured by ADSS, POEM and SCORAD), skin pain (skin pain NRS) and quality of life (DLQI) at 16 weeks compared to placebo. In addition, anxiety and depression symptoms as measured by the HADS total score were significantly reduced in the OLUMIANT groups compared to placebo at 16 weeks (See Table 16).

**Table 16 Quality of Life/Patient-Reported Outcomes results of OLUMIANT monotherapy and OLUMIANT in combination with TCS at week 16 (FAS) a**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Monotherapy** | | | | | | **TCS Combination** | | |
| **Study** | **BREEZE-AD1** | | | **BREEZE-AD2** | | | **BREEZE-AD7** | | |
| Treatment group | PBO | OLU  2 mg | OLU  4 mg | PBO | OLU  2 mg | OLU  4 mg | PBO + TCS | OLU  2 mg + TCS | OLU  4 mg + TCS |
| N | 249 | 123 | 125 | 244 | 123 | 123 | 109 | 109 | 111 |
| ADSS Item 2 change from baseline, LS mean (SE)b,c | -0.84 (0.15) | -1.04 (0.17) | -1.42\*\* (0.16) | -0.50 (0.12) | -1.03\*\* (0.13) | -1.13\*\*\* (0.13) | -0.51 (0.15) | -1.33\*\*\*f (0.15) | -1.42\*\*\*f (0.15) |
| Skin Pain NRS change from baseline, LS mean (SE)b | -0.84 (0.24) | -1.58 (0.29) | -1.93\*\* (0.26) | -0.86 (0.26) | -2.61\*\*\* (0.30) | -2.49\*\*\* (0.28) | -2.06 (0.23) | -3.22 \*\*\*f  (0.22) | -3.73\*\*\*f  (0.23) |
| POEM change from baseline, LS mean (SE)b, g | -2.68 (0.76) | -6.26\*\* (0.91) | -7.84\*\*\* (0.80) | -1.48 (0.84) | -7.06\*\*\* (0.96) | -7.56\*\*\* (0.88) | -5.60 (0.76) | -8.50\*\* (0.74) | -10.83\*\*\* (0.73) |
| POEM ≥ 4‑point improvement, % respondersd, e, g | 14.2% | 29.3%\*\*\* | 42.4%\*\*\* | 9.2% | 23.8%\*\*\* | 30.6%\*\*\* | 46.7 | 65.7\*\* | 70.6\*\*\* |
| DLQI change from baseline, LS mean (SE)b, g | -2.46 (0.57) | -4.30\* (0.68) | -6.76\*\*\* (0.60) | -3.35 (0.62) | -7.44\*\*\* (0.71) | -7.56\*\*\* (0.66) | -5.58 (0.61) | -7.50\* (0.58) | -8.89\*\*\* (0.58) |
| DLQI ≥ 4‑point improvement, % respondersd, e, g | 16.3% | 26.8%\* | 47.4%\*\*\* | 13.4% | 26.3%\*\* | 33.9%\*\*\* | 52.9 | 61.2 | 73.3\*\*\* |
| HADS change from baseline, LS mean (SE)b, g | -1.22 (0.48) | -3.22\*\* (0.58) | -3.56\*\*\* (0.52) | -1.25  (0.57) | -2.82 (0.66) | -3.71\*\* (0.62) | -3.18 (0.56) | -4.75\* (0.54) | -5.12\* (0.54) |
| HADS Anxiety Score < 8,  % respondersd, e, g | 12.0 | 18.4 | 41.0\*\*\* | 11.4 | 20.0 | 25.6\* | 45.5 | 54.8 | 56.1 |
| HADS Depression Score <8  % responders d, e, g | 13.0 | 17.4 | 35.7\* | 5.5 | 19.4\* | 16.0 | 30.3 | 66.7\* | 51.5 |

\*p ≤0.05; \*\*p ≤0.01; \*\*\*p ≤0.001 vs placebo

a Full analysis set (FAS) including all randomised patients.

b Results shown are LS mean change from baseline (SE). Data collected after rescue therapy or after permanent study drug discontinuation were considered missing.  LS means are from MMRM analyses which incorporates multiple imputation for missing data.

c ADSS Item 2: Mean number of night time awakenings due to itch

d Non-Responder Imputation: Patients who received rescue treatment or with missing data were considered as non-responders.

e Results shown in subset of patients eligible for assessment. For DLQI and POEM improvement, only patients with baseline severity of 4 or more points were included in the analysis. For HADS anxiety, and HADS Depression only patients with baseline severity of 8 or more points were included in the analysis.

f Not statistically significant after adjustment for multiple comparisons.

g Endpoint was not adjusted for multiplicity.

## Pharmacokinetic properties

### Absorption

Following oral administration, baricitinib is rapidly absorbed with a median tmax of approximately 1 hour and an absolute bioavailability of approximately 80%. Administration with meals was not associated with a clinically relevant effect on exposure.

### Distribution

Mean volume of distribution following intravenous infusion administration was 76 L, indicating distribution of baricitinib into tissues. Baricitinib is approximately 50% bound to plasma proteins. Baricitinib is a substrate of the Pgp, BCRP, OAT3 and MATE2-K transporters, which play roles in drug distribution.

### Metabolism

Baricitinib metabolism is mediated by CYP3A4 with approximately 6% of the dose identified as undergoing biotransformation. No metabolites were quantifiable in plasma. Baricitinib was excreted predominately as unchanged drug in urine (69%) and faeces (15%) and only 4 minor oxidative metabolites (3 in urine, 1 in faeces) were identified.

### Excretion

Renal elimination is the principal mechanism for baricitinib’s clearance through glomerular filtration and active secretion via OAT3, Pgp, BCRP and MATE2-K. In a clinical pharmacology study, approximately 75% of the administered dose was eliminated in the urine, while about 20% of the dose was eliminated in the faeces.

Mean apparent clearance (CL/F) and half-life in patients with rheumatoid arthritis was 9.42 L/hr (CV = 34.3%) and 12.5 hours (CV = 27.4%), respectively. Cmax and AUC at steady state were 1.4- and 2.0 fold higher, respectively, in patients with RA compared to healthy subjects.

Mean apparent clearance (CL/F) and half-life in patients with atopic dermatitis was 11.2 L/hr (CV = 33.0%) and 12.9 hrs (CV = 36.0%), respectively. Cmax and AUC at steady state in patients with atopic dermatitis are 0.8-fold those seen in rheumatoid arthritis.

*Other Intrinsic Factors*

Body weight, sex, race, and ethnicity did not have a clinically relevant effect on the pharmacokinetics (PK) of baricitinib. The mean effects of intrinsic factors on PK parameters (AUC and Cmax) were generally within the intersubject PK variability of baricitinib. Therefore, no dose adjustment is needed based on these patient factors.

*Renal Impairment*

Renal function was found to significantly affect baricitinib exposure. Subjects with moderate, Stage 3 renal impairment (GFR 30 - ≤60 mL/min/1.73m2) and severe, Stage 4 & 5 renal impairment (GFR <30 mL/min/1.73m2) have approximately 2-fold and 4-fold increases, respectively, in baricitinib AUC values compared to subjects with normal renal function.

The recommended dose of OLUMIANT in patients with estimated GFR of 30 - ≤60 mL/min/1.73 m2 is 2 mg once daily. OLUMIANT is not recommended for use in patients with estimated GFR of <30 mL/min/1.73 m2.

*Hepatic Impairment*

There was no clinically relevant effect on the PK of baricitinib in patients with mild or moderate hepatic impairment. No dose adjustment is necessary in these patients. The use of OLUMIANT has not been studied in patients with severe hepatic impairment and is therefore not recommended.

## Preclinical safety data

### Genotoxicity

Baricitinib was not genotoxic in bacterial reverse mutagenicity assays (Ames assay), in the in vitro human peripheral blood lymphocyte chromosomal aberration assay, or in the in vivo micronucleus assay in the rat. All assays were validated by the use of appropriate controls. The overall risk of genotoxicity is considered to be low.

### Carcinogenicity

Baricitinib did not produce neoplastic changes in two year rat and six month transgenic mouse carcinogenicity studies.

# Pharmaceutical particulars

## [List of excipients](#_Qualitative_and_quantitative)

croscarmellose sodium  
magnesium stearate  
mannitol  
microcrystalline cellulose  
iron oxide red  
lecithin  
macrogol 3350  
polyvinyl alcohol  
purified talc  
titanium dioxide

## Incompatibilities

Not applicable

## Shelf life

3 years

## Special precautions for storage

Stored below 30°C. Store in the original package

## Nature and contents of container


OLUMIANT is available as debossed, film-coated, immediate-release tablets in PVC/PE/PCTFE (Aclar)/Al or PA/Al/PVC/Al blister packs of 7 and 28.

## Special precautions for disposal

No special requirements for disposal.

## Physicochemical properties

### Chemical structure

The active ingredient in OLUMIANT® tablets is baricitinib. OLUMIANT is a Janus Kinase (JAK) inhibitor with the chemical name {1-(ethylsulfonyl)-3-[4-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)-1*H*-pyrazol-1-yl]azetidin-3-yl} acetonitrile. The empirical formula is C16H17N7O2S which corresponds to a molecular weight of 371.42 daltons. The chemical structure is:

### CAS number

The CAS number for baricitinib is 1187594-09-7.

# Medicine schedule (Poisons Standard)

S4 – Prescription Medicine

# Sponsor

Eli Lilly Australia Pty. Limited  
112 Wharf Road, West Ryde, NSW 2114  
AUSTRALIA

# Date of first approval

23 January 2018

# date of revision

11 February 2021

## Summary table of changes

|  |  |
| --- | --- |
| Section Changed | Summary of new information |
| 1, 4, 5 | New Indication |